Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 
Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 1 / 75   PROTOCOL  
The principles of the International Council for Harmonisation ( ICH) Guidelines for Good Clinical Practice 
(GCP E6 (R2)) will be applied to this study. 
CONFIDENTIAL: The information in this document contains trade s ecrets and commercial information that are privileged or confid ential and may not be 
disclosed unless such disclosure is required by [CONTACT_874437] e law or regulations. Subject to the foregoing, this informatio n may be disclosed only to those 
persons involved in the study who have a need to know, but all such persons must be instructed not to further disseminate this  information to others. 
These restrictions on disclosure will apply equally to all futu re information supplied to you, which is indicated as privilege d or confidential.PROTOCOL TITLE:  A 28-Day, Single-Center, Randomized, Comparator-Controlled, Pro of-
of-Principle Study to Assess Wound Healing Efficacies of Different 
Adhesive Bandages  
PROTOCOL NUMBER:  CCSTOH001689  
VERSION & DATE:  Amendment 3: Final Version 4.0, 28 Aug 2019 
Amendment 2: Final Version 3.0, 20 Aug 2019  
Amendment 1: Final Version 2.0, 12 Aug 2019  
Original: Final Version 1.0, 10 Jul 2019 
SPONSOR:  [COMPANY_012] Consumer Inc. 
[ADDRESS_1221134], Skillman, NJ [ZIP_CODE] [LOCATION_003]  
STUDY SITE:    
Tho
mas J. Stephens & Associates, Inc. , Dallas Research Center 
[ADDRESS_1221135]., Suite 200 
Richardson, [LOCATION_007] [ZIP_CODE] [LOCATION_003]  
 
PRINCIPAL INVESTIGATOR 
(PI): Lily Jiang, Ph.D. 
Address:  Refer to Study Site address  
  
SUB INVESTIGATOR (SUB-I):  
 
STUDY PHYSICIAN/SUB 
INVESTIGATOR (S UB-I): 
  
 
     
STUDY MANAGER (SM):   
  
   
STUDY DIRECTOR:  Robin Mathew, Ph.D.  
Address:  Refer to Sponsor address    
  
DEPARTMENT HEAD:    
  
   
HEAD OF CLINICAL 
RESEARCH:  
  
  
 
DESIGNATED PHYSICIAN 
REPRESENTATIVE (DPR) :  
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 2 / 75   VERSION TRACKING 
 
VERSION DATE STATE REASON FOR CHANGE  DESCRIPTION OF 
CHANGE 
1 10 Jul 2019  Obsolete  N/A - new protocol  N/A  
[ADDRESS_1221136] 
question #[ADDRESS_1221137] Screen Failure 
language , and clarify a few procedures 
in section 7 to match the Schedule  of 
Events in Table 2. See Summary of 
Changes in Appendix VIII.
 
3 20 Aug 2019 Obsolete  
 
 
 See Summary of 
Changes in Appendix IX.
 
4 28 Aug 2019 Issued  Continue clinical grading of wound 
healing parameters until Day 16 for all 
wound sites. See Summary of 
Changes in 
Appendix X. 
 
[Remainder of Page Intentionally Left Blank]  
  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 3 / 75   SYNOPSIS  
 
PROTOCOL TITLE  A 28-Day, Single-Center, Randomized, Comparator-Controlled, Pro of-
of-Principle Study to Assess Wound Healing Efficacies of Different 
Adhesive Bandages  
PROTOCOL NUMBER CCSTOH001689  
SPONSOR  [COMPANY_012] Consumer Inc. 
[ADDRESS_1221138], Skillman, NJ [ZIP_CODE] [LOCATION_003] 
STUDY SITE   
Tho
mas J. Stephens & Associates, Inc. , Dallas Research Center 
[ADDRESS_1221139]., Suite 200 
Richardson, [LOCATION_007] [ZIP_CODE] [LOCATION_003]  
 
PRINCIPAL INVESTIGATOR (PI) Lily Jiang, Ph.D. 
Address: Refer to Study Site address  
   
SUB-INVESTIGATOR (SUB-I):   
 
 
STUDY PHYSICIAN/SUB-
INVESTIGATOR (SUB -I): 
  
  
OBJECTIVE  The objective of this study is to assess the wound healing effi cacy 
(time to complete healing) of different adhesive bandages.  
 STUDY DESIGN  Single center, randomized, comparator-controlled, proof-of-prin ciple 
clinical trial.  
STUDY POPULATION  Healthy subjects who meet the eligibility criteria, including: 
x Males or females, 25 – 55 years old. 
x Fitzpatrick Skin Types II-III 
x Uniform skin color on both volar forearms  
SAMPLE SIZE  A sufficient number of subjects will be screened to enroll as m any as 
40 qualified subjects to ensu re completion of 30 subjects.  
INVESTIGATIONAL STUDY 
MATERIALS  Treatment 
Code/Identification UPC/PR#  Product type 
“Bandage” 
A – H  
(as randomly 
assigned by [CONTACT_2728]) 
 
   N/A – uncovered 
wound; Negative Control 
  
 Investigational Product 
(IP) –  
 
 
 
 IP – Benchmark Control 
1 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 4 / 75    IP – Benchmark Control 
[ADDRESS_1221140] at 
Baseline (Day 0) by [CONTACT_874438] a preassigned 
randomization scheme . The last wound site will be left uncovered as 
an untreated control.  
 
IPs* will be removed at the beginning of each study visit from Day 1 
(Visit 3)  through Day 16 (Visit 18) and replaced** at the end of each 
study visit from Day 1 (Visit 3) through Day 15 (Visit 17) .  
 
 
 
 
**Wound sites will remain uncovered once completely healed. 
STUDY DURATION  The study will be conducted over approximately 5 weeks with vis its 
at Screening (Day -7 to Day -3), daily from Baseline (Day 0) to Da y 16, 
on Day 21,  and at the end of the study on Day 28.  
METHODOLOGY  x Clinical Grading of Wound Healing Parameters (erythema, 
edema, epi[INVESTIGATOR_874395], crusting/scabbing, smoothness, 
and general wound appearance)  
x Scarring Assessment  
  
  
x TEWL Measurements  
x  
x Self-Assessment Questionnaire  
MEASUREMENT AND/OR EVALUATION SCHEDULE AND 
ASSOCIATED SUCCESS 
CRITERIA The following evaluations will be conducted for each wound site  at 
the indicated time  points: 
x Clinical Grading of Wound Healing Parameters (erythema, 
edema, epi[INVESTIGATOR_874395], crusting/scabbing, smoothness, 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 5 / 75   and general wound appearance) – Day 0 through Day 16* 
x Scarring Assessment - Day 0 and Day 28 
x  
  
x TEWL Measurements - Day 0 through Day 14* 
x 
 
 
x Self-Assessment Questionnaire - Day 0 through Day 4 
 
 
 
Success Criteri on: 
x 
 
STATISTICAL METHODS  All statistical analyses will be performed using the Statistica l Analysis 
System (SAS) v9.4 software. 
 
The statistical analysis will be performed by [CONTACT_874439].
 
 
All collected assessment data will be listed individually for a ll subjects. 
The following descriptive statistics will be presented: mean, s tandard 
deviation ( SD), median, minimum, and maximum. Percentage change 
from baseline will also be presented.  
 
The primary endpoint, time to complete heal ing, is defined as the 
time (in days) elapsed from the time of wound creation to 12PM of 
the day on which the wound is ev aluated as “completely healed.” 
 
Time to complete heal ing will be analyzed using a survival analysis 
method. The survival function (cumulative percentage of wounds 
healed at each time point) will be estimated by [CONTACT_8761] -Meier 
(KM) method for each treatment separately. The median time to 
complete heal ing will be derived from the estima ted survival function 
and be compared using the bo otstrap re-sampling method. 
 
  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 6 / [ADDRESS_1221141] OF ABBREVIATIONS 
 
Abbreviation Definition 
3D Three-Dimensional 
A.A.S. Associate of Applied Science 
AE Adverse Event 
BLT Benzocaine/Lidocaine/Tetracaine 
cm Centimeter 
cm2 Centimeter Squared 
C.M.L.S.O. Certified Medical Laser Safety Officer 
CRF Case Report Form 
DPR Designated Physician Representative 
EDC Electronic Data Capture 
EIU Exposure In Utero 
Er:YAG Erbium: Yttrium Aluminum Garnet 
f Focal Length 
FDA US Food and Drug Administration 
g Gram(s) 
h Hour 
HIPAA Health Insurance Portability and Accountability Act 
ICD Informed Consent Document 
ICH GCP International Council for Harmonisation Good Clinical Practice 
ID Identification 
IEC Independent Ethics Committee 
IP Investigational Product 
IRB Institutional Review Board 
ITT Intent-to-Treat 
J Joules 
kHz Kilohertz 
KM method Kaplan-Meier Method 
LLC Limited Liability Company 
m2 Meter Squared 
M.D. Doctor of Medicine 
mg Milligram 
mm Millimeter 
nm Nanometer 
  
Ph.D. Doctor of Philosophy 
PI [INVESTIGATOR_874396]-Treatment Adverse Event 
SAE Serious Adverse Event 
SD Standard Deviation 
SEM Standard Error of the Mean 
SM Study Manager 
SMF Site Master File 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 7 / 75   Abbreviation Definition 
  
SPF Sun Protection Factor 
TMF Trial Master File 
μm Micrometer 
W Watt 
 
      
 
 
         
 
 
        
 
   
 
     
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 8 / [ADDRESS_1221142] Responsibilities ............................... ............................................................... ..... 15 
4.3. CONCURRENT PRODUCTS ...................................... ............................................................. 1 6 
4.4. CONCURRENT/CONCOMITANT MEDICATION ........................ ............................................ [ADDRESS_1221143] QUALITY COMPLAINTS ............................... ........................................................ 18 
6.5. APPLICATION/USE OF THE INVE STIGATIONAL STUDY MATERIALS ... .................................. [ADDRESS_1221144] ................................... ............................................................... ............. 19 
6.5.2.   IPs .................................................. ............................................................... ...................... 19 
6.6. RANDOMIZATION/IP ALLOCATION AND BLINDING ................. ........................................... 22 
7. INVESTIGATIONAL PLAN ....................................... ............................................................... ............ 23 
7.1. STUDY DURATION ........................................... ............................................................... ..... 23 
7.2. STUDY PROCEDURES AND EVALUATION SCHEDULE ................. .......................................... 24 
7.2.1. Pre-Screening .......................................... ............................................................... ......... 25 
7.2.2. Visit 1/Screening (3 to 7 days prior to Visit 2) ....... ......................................................... 25 
7.2.3. Visit 2/Baseline (Day 0) – Pre-Wound Time Point ........ .................................................. 25 
7.2.4. Visit 2/Baseline (Day 0) – Wound Creation .............. ....................................................... 29 
7.2.5. Visit 2/Baseline (Day 0) – Post-Wound Time Point ....... .................................................. 29 
7.2.6. Visits 3-16 (Days 1-14) ................................ ............................................................... ...... 30 
7.2.7. Visit 17–18 (Day 15–16) ................................ ............................................................... ... 30 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 9 / 75   7.2.8. Visit 19 (Day 21) ...................................... ............................................................... ......... 31 
7.2.9. Visit 20 (Day 28) ...................................... ............................................................... ......... [ADDRESS_1221145] COMPLIANCE METRICS ............................... ......................................................... 33 
7.5. STUDY INSTRUMENTS ........................................ ............................................................... .. 33 
7.5.1.  
7.5.2. 
 3 4  
7.5.3. TEWL Measurements (Tewameter TM300 or TM330T; Courage + Khazaka, Köln, 
[LOCATION_013]) ...................................................... ................................................................................. [ADDRESS_1221146] COMPLETION/WITHDRAWAL ............................ ................................................... [ADDRESS_1221147] Discontinuation ................................ ............................................................... ... 35 
8. STATISTICAL ANALYSIS METHODS ............................... ............................................................... ..... 35 
8.1. SAMPLE SIZE DETERMINATION ................................ ........................................................... 36 
8.2. DATA ANALYSIS ............................................ ............................................................... ........ 36 
8.3. ENDPOINTS ................................................ ............................................................... .......... 36 
8.3.1. Primary Endpoints ...................................... ............................................................... ...... 36 
8.3.2. Secondary Endpoints .................................... ............................................................... ... 36 
8.3.3. Exploratory Endpoints .................................. ............................................................... .... 37 
8.4. AE ANALYSIS .............................................. ............................................................... ........... 37 
9. SUCCESS CRITERIA ........................................... ............................................................... ................. 38 
10. MANAGEMENT OF INTERCURRENT EVENTS ......................... .......................................................... 38 
10.1. AMENDMENTS TO  THE PROTOCOL............................... ...................................................... 38 
10.2. PROTOCOL DEVIATIONS ..................................... ............................................................... .. 38 
10.3. ADVERSE EVENT REPORTING ................................. ............................................................. 3 8 
10.3.1. Introduction .......................................... ............................................................... ........... 38 
10.3.2. Definitions ........................................... ............................................................... ............. 38 
10.3.3. Procedures for Reporting AEs .......................... ...............................................................  4 1 
10.3.4. Monitoring and Resolution of AEs ...................... ............................................................ 43  
10.3.5. Pregnancy Reporting and Exposure In Utero (EIU) ....... .................................................. [ADDRESS_1221148]/INDEPENDENT ETHI CS COMMITTEE ... 44 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 10 / [ADDRESS_1221149] KEEPI[INVESTIGATOR_1645] .......................... .............................................................. 45 
13. STUDY MONITORING, QUALITY CONTROL, AND QUALITY ASSURANCE .. ....................................... 46 
14. SPONSOR DISCONTINUATION CRITERIA .......................... ...............................................................  4 7 
15. FINAL REPORT .............................................. ............................................................... .................... 47 
16. CONFIDENTIALITY ........................................... ............................................................... .................. 47 
17. PUBLICATION ............................................... ............................................................... ..................... 47 
18. BIBLIOGRAPHIC  REFEREN CES .................................. ............................................................... ......... 48 
20. PRINCIPAL INVESTIGATOR [INVESTIGATOR_874397] ........... .................................................... 50 
21. APPENDICES ................................................ ............................................................... ..................... 51 
Appendix I.  Fitzpatrick Sk in Type Classification ............. ............................................................... ...... 52 
Appendix II. Body Mass Index Table6 .............................................................. .................................... 53 
Appendix III. Subjec t Instructions ............................ ............................................................... .............. 54 
Appendix IV. Ingredient Listing ............................... ............................................................... ............... 55 
Appendix V. Temporary (Semi-Permanent) Dot-Tattoo Procedure7 ................................................... [ADDRESS_1221150] Self-Assessment Questionnaire (Day 0 throu gh Day 4) ..................................... [ADDRESS_1221151] Information ............................. ............................................................... ............ 58 
Appendix VIII.   S ummary of Changes – Amendment 1 ............. .............................................................. 60 
Appendix IX.   Summary of C hanges – Amendment 2 ............... ............................................................ 64  
Appendix X.   Summary of C hanges – Amendment 3 ................ ........................................................... 72 
 
      
 
   
 
     
 
 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 11 / [ADDRESS_1221152] environment may promote the restoration of epi[INVESTIGATOR_874398] g changes relatively easier. Moreover, it 
has been suggested that the scar  left by [CONTACT_874440].
3  
 
 
 
 
 
 
 
 
 
 
 
 2. OBJECTIVE  The objective of this study is to assess the wound healing effi cacy (time to complete healing) of different 
adhesive bandages.   
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 12 / [ADDRESS_1221153] 30 subjects.   At Screening (Visit 1; 3 to 7 days prior to Baseline), subjects  will be provided with an auxiliary cleanser to 
use on their forearms and for all body cleansing in place of th eir regular body cleanser for the duration of 
the study.  
At Baseline (Visit 2), a Sciton Er:YAG 2940 laser will be used to induce eight partial-thickness (i.e. minor) 
wounds on the subjects’ forearms (four per arm).4  The wounds created by [CONTACT_874441][INVESTIGATOR_874399]’s base (dermal islands) 
and/or wound borders, and mimic minor wounds similar to real li fe scraped skin, typi[INVESTIGATOR_874400] 14 days if left untreated, based on the Site’s previo us experience.   
 Each wound site will be  and a ssessed at pre-specified intervals by [CONTACT_874442] (until Day 16),  
  In addition, subjects will assess the wound sites via que s t i o n n a i r e  f r o m  D a y  0  t o  D a y  4 ,   
 
 
 Between Baseline and Day 16, each wound site will be subjected to one of eight randomly-assigned 
treatments (see section 6) until day of complete healing.  Trea tments include an adhesive bandage that is 
considered the  a marketed adhesive bandage benchmark contr ol, a non-marketed adhesive bandage 
benchmark control, four non-mark eted adhesive bandages, and no treatment (uncovered, negative 
control).   
 
 
Once a wound site has completely healed, bandage c hanges will be discontinued and the 
wound will be left uncovered.   
All wound sites will be uncovered from Day [ADDRESS_1221154] subjects for whom protocol procedures are co nsidered appropriate. 
 
All relevant medical and non-me dical conditions should be taken  into consideration, in addition to the 
inclusion/exclusion criteria belo w, when deciding if a particul ar individual is suitable for this protocol.  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 13 / 75   No type of discrimination (e.g. social class, gender, skin colo r, ethnicity, etc.) should preclude an eligible 
subject from participating in the study.  Information that is n ot relevant to the conduct of the study should 
not be collected.  
Prior to any review of personal data, the Informed Consent Docu ment (ICD) should be signed. 
 4.1. INFORMED CONSENT   
 The ICD must be read by [CONTACT_874443] t by [CONTACT_978] [INVESTIGATOR_1461].   
 The PI [INVESTIGATOR_874401] t hat each study subject is fully  informed about the nature and objectives 
of the study and possible risks associated with participation. After understanding and agreeing, the subject 
will express his/her consent to his/her  participation in the study by [CONTACT_874444].   
 
The ICD will be signed and dated by [CONTACT_1633]/designee and by  [CONTACT_423].  The signed and dated original 
will be kept in the Site Master File (SMF) and a signed and dat ed copy must be given to the subject.   
 No subject will be evaluated without a signed and dated ICD, wh ich should be kept by [CONTACT_978]/Site as part 
of the SMF. The ICDs of subjects who are not included in the st udy will also be part of the SMF.  
 The ICD must be approved by [CONTACT_874445] R eview Board/Independent Ethics 
Committee (IRB/IEC) and must be in compliance with the principl es of ICH GCP, local regulatory 
requirements, and legal requirements.  
4.2. STUDY POPULATION 
 
The PI [INVESTIGATOR_874402] c riteria and none of the exclusion criteria to 
be included in the study. Waivers to inclusion or exclusion cri teria are not permitted. In addition, the PI [INVESTIGATOR_874403]. 
 The initial verification of eligibility, including review of me dical history and concomitant medications, may 
be conducted by a non-medically qualified individual (PI [INVESTIGATOR_338816]).  
 The eligibility must then be reviewed and confirmed by a medica lly qualified individual (the Study 
Physician) before enrollment. The medically qualified individua l is not required to review the eligibility 
information if the potential subject is screen-failed by [CONTACT_639226] n-medically qualified staff.  
4.2.1. Inclusion Criteria 
 
a) Male or female 
b) 25 to 55 years old 
c) Fitzpatrick Skin Type II or III  (see Appendix I)  
d) Uniform skin color on both volar forearms. 
e) Generally in good health based on medical history reported by t he subject. 
f) Able to read, write, speak, and understand English. 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 14 / 75   g) Individual has signed the Consent for Photograph Release and IC D including Health Insurance 
Portability and Accountability Act (HIPAA) disclosure.  
h) Has access to a computer or phone with internet access and the ability to complete online 
questionnaires. 
i) Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms. 
j) Willing to undergo topi[INVESTIGATOR_874404]. 
k) Intends to complete the study and is willing and able to follow  all study instructions (see section 
4.2.3).  
4.2.2. Exclusion Criteria 
 
a) Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, 
latex, wound treatment products, or any component/ingredient pr esent in the 
IPs/auxiliary/ancillary products.  
b) Has a known history of a blood-clotting disorder, keloid for mation, or a cardiovascular, hepatic, 
or renal disease. 
c) Presents with a skin condition that would, in the opi[INVESTIGATOR_874405], confound 
the study results, increase risk to the subject, or interfere w ith study evaluations (e.g., active 
psoriasis, seborrheic dermatitis, atopic dermatitis, skin derma toses, keloids, hypertrophic scars, 
cracked/excoriated skin, acne scars, pi[INVESTIGATOR_371], friable skin , or clinically infected skin lesions). 
d) Has excessive hair or tatto os on either volar forearm. 
e )  H a s  a  k n o w n  h i s t o r y  o f  s e v e r e  s y s t e m i c  i m m u n e  s y s t e m  d i s o r d e rs such as Systemic Lupus 
Erythematosus (SLE), Rheumatoid Arthritis (RA), Scleroderma, ch ronic connective tissue 
disorders, Poly Arteritis Nodosa, or immunodeficiency, includin g HIV infection. 
f) Has self-reported Type 1 or Type 2 diabetes or is taking ins ulin or another anti-diabetic medication.  
g) Has self-reported uncontrolled chronic diseases such as  hypertension, hyperthyroidism, 
hypothyroidism, or active or recently treated (within 1 year) s kin cancer.  
h) Is taking a medication that would mask an Adverse Event (AE) , confound the study results, or alter or 
compromise the bleeding/healing process including:  
x Antibiotics, corticosteroids, immunosuppressive agents, anti-co agulants, antiplatelet drugs, cytotoxic 
agents, continuous aspi[INVESTIGATOR_119457], chemotherapy, or daily medi cations for chronic asthma, within 1 
month before Visit 1.* 
x Non-steroidal anti-inflammatory drugs or steroidal drugs within  5  d a y s  b e f o r e  V i s i t  1 . *  L o w  d o s e  
aspi[INVESTIGATOR_248] (81 mg per day) is allowed. 
x Antihistamines within 2 weeks before Visit 1.* 
* If an individual is taking one of these medication types, the  individual is not considered eligible at 
screening.  However, if a subject begins using one of these med ications during the study, the Study 
Physician should be consulted to consider the impact of the spe cific medication on subject safety 
and/or the study results as desc ribed in section 0 (“Concurrent /Concomitant Medication”). 
i) Is self-reported to be pregnant or planning to become pregna nt during the study. 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 15 / 75   j) Has taken/used (oral or topi[INVESTIGATOR_2855]) vitamin A derivatives such as Accutane, isotretinoin, or retinoic acid 
within the past 1 year. 
k) Has used topi[INVESTIGATOR_874406]-on products on the volar forearms within  1 week prior to Visit 1.  
l) Is participating or has particip ated in 1) any clinical trial i nvolving a topi[INVESTIGATOR_874407] 30 days prior to Visit 1 or 2) any other clinical study within 10 days 
prior to Visit 1. 
m) Has a body mass index (BMI) above 35 on the BMI scale (see Appe ndix II), based on the subject’s self-
reported height and weight.  
n) Is self-reported to be an alcohol or drug abuser.  
o) Is an employee/contractor or imme diate family member of the PI,  Study Site, or Sponsor. 
p) Either is or lives with someone who is a current employee of an y company that makes or markets 
adhesive bandages or first aid products. 
q) Has a history of or a concurrent health/other condition/situati on which may put the individual at 
significant risk, confound the study results, or interfere sign ificantly with the individual’s participation 
in the study. 
4.2.3. Subject Responsibilities 
 During the study, the subject should follow the instructions be low: 
 
x Use the provided cleanser on your forearms and body for the dur ation of the study in place of 
your normal body cleanser. Do not use any other products on you r forearms during the study.  
For the rest of the body, continue using your normal skincare p roducts; do not start using any 
new products/brands.  
x Do not wet or put your forearms in water for the duration of th e study (i.e., swimming, baths, hot 
tubs, etc.). Only showering is acceptable. 
x Do not shower within [ADDRESS_1221155] sites to sunlight or use tanning booths/ beds during the study. 
x Wear long sleeves when going outdoors and for the first 12 hour s after each tattoo application 
(ink may transfer to other skin locations). 
x Avoid touching/scratching the test sites. 
x Leave the test products (the bandages) on your forearms – only the study site should remove or 
apply them.  If the bandages become loose between clinic visits , you may use the provided tape 
to secure the bandage; apply the tape only on the adhesive part s of the bandage (not on the pad 
or middle of the bandage). 
x If any test product (bandage) falls off, record the date and ti me that the bandage fell off and 
report that information at your next visit. Do not try to reapp ly any bandage if it falls off. Please 
bring the bandage that has fallen off to your next visit. 
x Whenever possible, inform the study team before you start using  any new medication.  
x Avoid pregnancy by [CONTACT_874446] a medically acceptable con
traception method, if applicable. 
x Attend all study visits at th e scheduled time and date. 
x Do not start any other studies during this study. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 16 / [ADDRESS_1221156] of their 
normal body cleanser.  They should not use any other products o n their forearms during the study (other 
than the auxiliary product and IPs).  For the rest of their bod y, they should continue using their normal 
skincare products and not start us ing any new products/brands. 
 4.4. CONCURRENT/CONCOMITANT MEDICATION  If a subject is taking any medication during the course of the study and/or within [ADDRESS_1221157] be recorded. The minimum information that is req uired is the name [CONTACT_11889]. 
 If this medication is linked to the treatment of an IP-related or study-related AE, the dose and duration of 
the treatment should be specified. 
 
Medications excluded are indicated in the section “Exclusion Cr iteria” ; if a subject begins using an 
excluded medication during the study, the Study Physician must consider whether it will impact the 
subject’s safety and/or confound study results and document the  decision. In case of impact, the subject 
should be discontinued.
 
  4.5. SCREEN FAILURE  All individuals who sign the ICD and withdraw their consent  for participation in the study or fail to meet 
at least one of the eligibility criteria during the initial eva luation will be considered a “screen failure” and 
their data will be entered in th e Electronic Data Capture (EDC)  system and the AEs will be included in the 
final report . 
 
5. SAMPLE SIZE   A sufficient number of subjects will be screened to enroll as m any as [ADDRESS_1221158] 30 subjects.  If the final sample size is smaller than expected, a protocol d eviation should be recorded and 
communicated to the Sponsor. 
 
6. INVESTIGATIONAL STUDY MATERIALS   The Sponsor has ensured that there is sufficient safety data to  support the human use of the 
investigational study materials  (IPs and auxiliary product). 
     
 
 
 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 17 / [ADDRESS_1221159] will be provided under authorization of  the Sponsor: 
 
Table 1. IP and Auxiliary Product List/Study Treatments 
Treatment 
Code/Identification UPC/PR #  Product type Regulatory Class in [LOCATION_003] 
“Bandage” 
A – H 
(as randomly assigned 
by [CONTACT_2728])   N/A - uncovered wound; 
Negative Control N/A 
 IP –   
 IP – Benchmark Control 1  
 IP – Benchmark Control [ADDRESS_1221160] is provided in Ap pendix IV. 
 All the investigational study materials will be manufactured ac cording to Good Manufacturing Practices. 
 6.2. LABELING 
 
The Sponsor will affix a study label to each IP or kit of IP.  The study labels will contain (but are not limited 
to) the following information, consistent with the requirements  of 21 CFR 812.5: 
 
x Protocol number 
x Treatment Code 
x The name [CONTACT_874471] (in accordance with 21 CFR 801.1) 
x The quantity of the contents 
x Caution statement (“CAUTION - Investigational device. Limited b y [LOCATION_002] law to 
investigational use”).  
x All relevant contradictions, hazards, adverse effects, interfer ing substances or devices, warnings, 
and precautions for the device that are not captured in the ICD /study instructions. 
 
A partial label will be affixed to each auxiliary product. The label may contain (but is not limited to) fields 
for the following information: 
x Protocol number 
x “For Participant Use Only” 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 18 / [ADDRESS_1221161] Information 
x Unit # 
6.3. STORAGE AND ACCOUNTABILITY 
 The IPs and auxiliary product for this study will be secured in  a room or cabinet that is only accessible to 
Study Site authorized personnel and kept at room temperature (1 5 - 30°C or 59 - 86°F), with temperature 
recorded daily.  
 
The PI [INVESTIGATOR_874408] t he receipt, use, loss, or other 
disposition of the IPs and auxiliary product on the Product Dis pensing and Accountability Log (or 
equivalent), which must be filed in the SMF.
 
 The log must identify the IPs and auxiliary product and account  for the disposition including specific dates 
and quantities used/dispensed and returned, as applicable.  The log must be signed by [CONTACT_874447]/dispensed and retrieved the IPs and auxiliary 
product and a copy of the log must be provided to the Sponsor. 
 
At the end of the study, all unused units of the IPs and all un its of the auxiliary product (used and/or 
unused) must be returned to the Sponsor at the following addres s: 
 
[COMPANY_012] Consumer Inc. [ADDRESS_1221162] 
Skillman, NJ [ZIP_CODE] [LOCATION_003] 
Attn: Clinical Supplies 
 The Sponsor will provide the return forms. 
 
All used units of the IP will be destroyed by [CONTACT_874448] g its standard operating procedures for 
biohazardous waste.   Proof of destruction must be provided to the Sponsor.  
 6.4. PRODUCT QUALITY COMPLAINTS  A Product Quality Complaint (PQC) is any written, electronic, o r oral communication that alleges 
deficiencies related to the identity, quality, durability, reli ability, or safety of a product, including its 
labeling, delivery system, or packaging integrity.  It also inc ludes device malfunctions. 
 
No PQC form should be filed for issues identified during receip t/inventory of a shipment. Instead, these 
should be reported as indicated on the receipt letter.  Subsequently, any observation/report of a PQC requires immediat e notification of the Sponsor. The PI [INVESTIGATOR_874409], sign, a nd securely send a copy of the  PQC form to the SM.  
  The PI/Site staff is 
responsible for detecting and reporting PQCs and for instructin g  s u b j e c t s  t o  d o  t h e  s a m e ,  w h e n e v e r  
applicable. The PI/Site staff must also ensure that products pr esenting PQCs are not used or that they have 
their use interrupted upon the identification of a PQC. 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 19 / [ADDRESS_1221163] Dispensing  and Accountability Log (or equivalent). 
 
The SM can provide assistance and answer questions related to t his process. To aid in the initial 
conversation and understanding of a PQC, the Site staff may be asked to photograph the issue and send 
the photograph to the SM. The SM will coordinate the replacemen t or return of the affected products, if 
necessary.  6.5. APPLICATION/USE OF THE INVESTIGATIONAL STUDY MATERIALS 
6.5.1.    Auxiliary Product 
 At Screening (Visit 1), subjects will be provided with the auxiliary cleanser to use on their forearms and 
for all body cleansing in place of their regular body cleanser for the duration of the study.  The labeled 
directions will be as indicated below:  
 
  
Use this cleanser on your forearms and body in place of your no rmal body cleanser.  Wet your skin 
with warm water, apply wash with your hand or washcloth, gently lather, and rinse. 
 Do not use any other products on your forearms for the duration  of the study. 
 See section 4.2.3 and Appendix III for overall study instructio ns. 
6.5.2.   IPs  
All IP application and removal  will be performed at the study site as described below by [CONTACT_874449] (see  section 6.6).  
 
 
 
 
 
 
 
 Each IP unit 
is for single use; used bandages will not be re-applied and sho uld be discarded by [CONTACT_874450] 6.3. 
IP will be applied by a designated study staff member as follow s: 
  
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 20 / 75    
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 21 / 75   Additional application details for all IPs: 
x If a wound shows signs of excessive redness, pain, or swelling or signs of infection 
(which should be documented as an AE, per section [IP_ADDRESS]), IP will not be applied. 
x  
 
 
 Subjects will also be provided a roll of tape to take home for use in case IPs 
become loose between clinic visits.   
x If an IP falls off at home, subjects will be instructed to repo rt the date and time that the 
IP fell off and report that information at their next visit.  I Ps will not be replaced at home 
if they fall off.  Subjects will be instructed to retain any IP s that have fallen off and bring 
them to their next appointment. 
  
 
 
  
 
IP will be removed by a designated study staff member as follow s: 
 
 
  
 
 
 
  
  
 
                   
 
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 22 / 75    
 
 
 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
    
 
 6.6. RANDOMIZATION/IP ALLOCATION AND BLINDING 
 
Upon signing the ICD, each subject will be sequentially issued an eight-digit subject ID. The first four digits 
will be the center ID, 1001, and the next four digits will be a  unique subject identifier assigned in ascending 
numerical order beginning with 1001 (i.e. subject ID 10011001, 10011002, 10011003, etc.).  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 23 / [ADDRESS_1221164] at 
the Baseline visit (Visit 2). Once a randomization number has b een assigned to a subject, it cannot be 
reassigned to another subject. 
 
Randomization of the study treatments to the eight wound sites (see section [IP_ADDRESS]; one study treatment 
per wound site) will be based on a randomization scheme devised  by [CONTACT_874451] (A through H).  
 
 
Due to the nature of the IPs and the study design, it is not fe asible to fully blind the IPs or to conceal the 
treatment assignments from study subjects or from all study personnel (i.e. those involved in applying/removing the IPs, IP accountability, or assessing subj ect compliance).  Staff responsible for IP 
accountability and IP application/removal (hereafter “unblinded  staff”) will have access to the 
randomization schedule in order to accurately administer the st udy treatments.  The unblinded staff will 
not complete any subject evaluations other than the interview f or compliance/AEs.   
 The PI [INVESTIGATOR_874410] w for compliance/AEs (hereafter “blinded 
staff”) will not have access to the randomization schedule, and  the IPs will be kept separate from the 
blinded staff.  Subjects will be instructed not to disclose information about their assigned study treatments to blinded staff, or to discuss any other information that may reveal the treatment assignment.  
 
 
 
 
   
 
The randomization schedule will be used by [CONTACT_874452]-specific disclosure 
envelopes.  In the event that the PI [INVESTIGATOR_874411], the PI [INVESTIGATOR_874412] c ontact the SM who will consult with the DPR to determine whether a code 
break is needed.  If there is a medical emergency and the PI [INVESTIGATOR_874413]’s proper medical care, the PI [INVESTIGATOR_874414]-specific envelope.  The time, date, 
and reason for the unblinding should be noted in the subject’s source document and documentation 
should be provided to the Sponsor.  Blinding should only be bro ken for serious, unexpected, and related 
AEs, and only for the subject/treatment code in question, or wh en required by [CONTACT_31665]. 
 
All disclosure envelopes must be returned to the Sponsor at the  conclusion of the study. 
 7. INVESTIGATIONAL PLAN  7.1. STUDY DURATION  The study will consist of 20 visits over approximately 5 weeks with visits scheduled at Screening (Visit 1, 3 
to 7 days prior to Visit 2), Day 0 (Visit 2, Baseline/Pre-Wound  and Post-Wound time points), daily on Days 
1 through Day 16 (Visit 3 through Visit 18), Day 21 (Visit 19),  and Day 28 (Visit 20).  A subject’s Day 0 
through Day 28 study visits should be scheduled at approximatel y the same time of day for each visit (i.e., 
morning, afternoon, or evening). 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of Different Adhesive Bandages 
Protocol Number: CCSTOH001689 
Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 24 / 75   7.2. STUDY PROCEDURES AND EVALUATION SCHEDULE 
The table below presents a summary of the study procedures and evaluation schedule. 
Table 2. Schedule of Events 
Procedures:  Visit: 1 
Screening 2 
Baseline 
(Pre-Wound) 2  
(Post-
Wound) 3 & 4 5 6 7, 9, 11, 
13, & 15 8, 10, 
12, & 14 16 17 18 19 20 
Day: -7 to -3  0 0 1 & 2 3 4 5, 7, 9, 
11 & 13 6, 8, 10 
& 12 14 15 16 21 28 
ICD with HIPAA disclosure & Photo Release X             
Demographics, medical history, and conmeds 
collection X             
Review of eligibility/enrollment X             
Dispense auxiliary cleanser & study instructions  X             
Interview for compliance and changes in 
health/AEs/conmeds   X  X 
(AEs only) X X X X X X X X X X 
Randomization   X            
 
   XA XA XA XA XA XA XA XA XA XA XA  
Test site label application  X X X X X X X X X X X X 
IP Removal    XB X XB X XB XB X X   
5-min acclimation  X X XB X XB X XB XB X X  X 
Clinical grading of wound healing parameters  X X XB X XB X XB XB X X   
Scarring assessment   X           X 
  X X XB X XB X XB XB X X X X 
  X X XB X XB X XB XB     
TEWL measurements  X X XB X XB X XB XB     
  X  XD  X 
BLT cream application (30 min prior to wounding)   X            
Test site cleaning and wounding  X            
IP applicationE    X XB X XB X XB XB X    
Subject self-assessment questionnaire   XC X X X        
Collect auxiliary product             X 
  
 
CAssessment will be completed rem otely approximately 3-4 hours a fter BLT cream application once numbness is gone. 
DAt time of complete healing for a particular wound site.  
ECompletely healed wound sites wi ll be left uncovered for the re mainder of the study. 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 25 / 75   7.2.1. Pre-Screening 
 Potential subjects will be pre-screened using IRB-approved mate rials.  Subjects who meet the pre-
screening eligibility criteria will be given an appointment tim e for their screening visit. 
7.2.2. Visit 1/Screening (3 to 7 days prior to Visit 2) 
 [IP_ADDRESS].        Informed Consent  Informed consent will be obtained as described in section 4.1.  The ICD will include a HIPAA disclosure and 
a Photograph Release Form.  Subjects who sign the ICD will be s equentially assigned a subject ID (see 
section 6.6). 
 
[IP_ADDRESS].        Demographics, Medical History, Concomitant Medi cations, BMI, and Review of Eligibility 
 
The demographics, medical history, and concomitant medications of each candidate subject will be 
collected and reviewed.  BMI will be calculated using the subject’s self-reported height  and weight and the Body Mass Index Table 
(Appendix II).  All of the eligibility requirements of the study will also be r eviewed to assess each candidate subject’s 
eligibility, according to the inclusion/exclusion criteria. As part of this review, trained study personnel will 
examine the subject’s volar forearms to determine if the subjec t meets the eligibility criteria. 
 
The Study Physician will review the above information (medical history, concomitant medications, and 
eligibility review) to confirm the eligibility of each subject prior to their enrollment in the study as 
described in section 4.2.  [IP_ADDRESS].        Distribution of Auxiliary Cleanser  Enrolled subjects will be provided with a unit of the auxiliary  cleanser along with written and verbal study 
instructions (Appendix III).    
7.2.3. Visit 2/Baseline (Day 0) – Pre-Wound Time Point  
 
Subjects will return to the clinic for Visit 2.  The following study procedures will be performed at the 
Baseline/Pre-Wound time point:   
 [IP_ADDRESS].  Interview for Compliance, Changes in Health/ConMeds, and AEs  
 Subjects will be interviewed for compliance with study instruct ions and for any changes in their health or 
concomitant medications.  Any AEs will be recorded.  [IP_ADDRESS].  Randomization 
 
A unique randomization number will be assigned to each subject as described in section 6.6. 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 26 / 75   [IP_ADDRESS].  Identification of Test Sites and Application of Tempo rary (Semi-Permanent) Dot-Tattoos and 
Test Site Labels 
 Eight test sites (i.e. wound sites) will be identified on the v olar forearms, four on each forearm, as shown 
in Figure 6.  
 
Figure 6.  Wound Site Placement 
                             
Going from the elbow to the wrist, the test sites on the right volar forearm will be designated test sites 1, 
2, 3, and 4, and those on the left volar forearm will be design ated test sites 5, 6, 7, and 8.  The test sites 
will be spaced such that the wounds (see section [IP_ADDRESS].) will  be created at least 4.0 cm apart so that the 
IPs will not overlap when applied.      
 
 
  
 
 
 
 
 
[IP_ADDRESS].  Acclimation  
 
Subjects will acclimate in a controlled environment with the re lative humidity maintained at 35-60% and 
temperature maintained at 19-22°C in the test facility for at l east 5 minutes before further evaluations 
are performed.  
[IP_ADDRESS].  Clinical Grading of Wound Healing Parameters  
 
After the acclimation period is complete, clinical grading of e ach test site will be performed by [CONTACT_978] [INVESTIGATOR_874415]:  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 27 / 75   x Erythema  
0 = none/absent 
1 = mild 
2 = moderate 
3 = marked 4 = severe 
 
x Edema  
0 = none/absent 
1 = mild 2 = moderate 3 = marked 
4 = severe 
 
x Epi[INVESTIGATOR_874416] 
0 = none, no epi[INVESTIGATOR_874417]  
1 = slight (up to 30%) 2 = moderate (31-60%) 3 = extensive (61-90%) 4 = almost complete or complete (91-100%), covered with a full layer of new epi[INVESTIGATOR_192797] 
 
x Crusting/Scabbing 
0 = none 
1 = slight (up to 30%) 2 = moderate (31%-60%) 
3 = extensive (61%- 90%) 
4 = almost complete or complete (91%-100%)  
 
x Smoothness 
0 = rough, uneven wound 
1 = mild smoothness 2 = moderate smoothness 3 = extensive smoothness 4 = complete smooth, even wound 
 
x General Wound Appearance 
0 = Poor  
1 = Fair 
2 = Good 
3 = Very good 4 = Excellent 
 Half-point grading will be allowed.    
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 28 / 75   [IP_ADDRESS].     Scarring Assessment 
 
A scarring assessment of each test site will be performed by [CONTACT_3433] e PI [INVESTIGATOR_874418]5 as follows:  
 
x Color 
1 = Perfect 2 = Slight mismatch with surrounding skin 3 = Obvious mismatch with surrounding skin 4 = Gross mismatch with surrounding skin  
x Finish (matte versus shiny) 
1 = Matte 
2 = Shiny 
 
x Contour 
1 = Flush with surrounding skin 2 = Slightly proud/indented 3 = Hypertrophic 4 = Keloid 
 
x Distortion 
1 = None 
2 = Mild 3 = Moderate 
4 = Severe 
 
x Texture 
1 = Normal 2 = Just palpable 3 = Firm 4 = Hard  
[IP_ADDRESS].  Instrumental Assessments  
 
 
 
  
 
 7.2.3.
7.3.  Trans-Epi[INVESTIGATOR_3915] W ater Loss (TEWL) Measurements 
 TEWL measurements will be performed on each test site as descri bed in section 7.5.3. 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 29 / 75     
 
7.2.4. Visit 2/Baseline (Day 0) – Wound Creation  
 
[IP_ADDRESS]. Benzocaine/Lidocaine/Tetracaine Cream Application  Anhydrous numbing Benzocaine/Lidocaine/Tetracaine (BLT) cream ( 20%/8%/8%) will be topi[INVESTIGATOR_874419] a thick layer (approximately 2 cm x 2 cm area) at ea ch test site, approximately 30 minutes 
prior to wounding procedure.   [IP_ADDRESS]. Wound Site Cleaning 
 
The subjects’ forearms will be cleaned with alcohol wipes after  the cream application before the wounding 
procedure is performed.  [IP_ADDRESS]. Wounding Procedure with Er:YAG 2940 Laser (Sciton, Pal o Alto, CA, [LOCATION_003])  
 A certified laser specialist will create [ADDRESS_1221165] at the 
designated wound sites (see section [IP_ADDRESS]) using a Sciton Er: YAG 2940 laser.  
x The wounds will be induced with er bium at an energy setting of 12.2 J/cm2 
x Number of passes:  3 passes of ~50μm depth per pass 
x Each wound will be a circle, [ADDRESS_1221166] 4 cm apart, as indicated in se ction [IP_ADDRESS]. 
7.2.5. Visit 2/Baseline (Day 0) – Post-Wound Time Point  [IP_ADDRESS]. Clinical/Instrumental Evaluations  After wound creation, the following evaluations will be complet ed on each test site in the order below: 
x Clinical grading of wound healing parameters, as described in s ection [IP_ADDRESS]. 
x  
x  
x TEWL Measurements, as described in section [IP_ADDRESS].3  
[IP_ADDRESS]. IP Application  
After completion of the clinical grading and instrumental evaluations, IPs will be applied to the randomly 
assigned test sites, as described in section 6.  The untreated test site will remain uncovered. 
 Subjects will be reminded of the study instructions (Appendix III).   [IP_ADDRESS]. Self-Assessment Questionnaire  Subjects will be asked to remotely complete a self-assessment q uestionnaire (see Appendix VI) 
approximately 3-4 hours after the BLT cream application, when n umbness is gone. 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 30 / 75   7.2.6. Visits 3-16 (Days 1-14)  
 
The following procedures will be completed: 
x Subjects will be interviewed for any changes in their medical h istory or concomitant medications 
since the last visit.  Any AEs will be recorded. 
x  
   
  
   
x Test site labels will be applied as described in section 7.2.3. 3. 
x  
  
 
 
 
x Subjects will acclimate as described in section [IP_ADDRESS].   
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
o Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
o Instrumental measurements, as described in section [IP_ADDRESS]. 
o  
x The designated IP will be applied to each test site per the randomization schedule.i 
x At Visits 3-6:  Subjects will complete the self-assessment ques t i o n n a i r e  a t  t h e  s t u d y  s i t e  
(Appendix VI) after the IP application. 
 
7.2.7. Visit 17–18 (Day 15–16)  The following procedures will be completed: 
x Subjects will be interviewed for any changes in their medical h istory or concomitant medications 
since the last visit.  Any AEs will be recorded. 
x  
  
  
  
x Test site labels will be applied as described in section 7.2.3. 3. 
x All IPs will be removed from the wound sites prior to acclimati on. 
x Subjects will acclimate as described in section [IP_ADDRESS].   
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
x Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
x   
  
   
                                                           
 
i Completely healed wou nd sites will be left uncovered for the r emainder of the study.  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 31 / 75   x At Visit 17: The designated IP will be applied to each test sit e per the randomization schedule.ii 
x At Visit 18: Subjects will be reminded of the study instruction s. Wound sites will remain 
uncovered for the remainder of the study. 
 
7.2.8. Visit 19 (Day 21)   The following procedures will be completed: 
x Subjects will be interviewed for any changes in their medical h istory or concomitant medications 
since the last visit.  Any AEs will be recorded. 
x  
 
 
   
  
x  
 
7.2.9. Visit 20 (Day 28)   
The following procedures will be completed: 
x Subjects will be interviewed for any changes in their medical h istory or concomitant medications 
since the last visit.  Any AEs will be recorded. 
x Test site labels will be applied as described in section 7.2.3. 3. 
x Subjects will acclimate as described in section [IP_ADDRESS].   
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
x Scar assessment, as described in section [IP_ADDRESS] 
x  
 
x The auxiliary cleanser will be collected.  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
__________________________ 
 
ii Completely healed wound sites wi ll be left uncovered for the re mainder of the study.  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 32 / 75    
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 33 / [ADDRESS_1221167] visits or other noncompliance will be docume nted as a protocol deviation. 
   
7.5. STUDY INSTRUMENTS 
 
 
 
 
 
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 34 / 75    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
7.5.3. TEWL Measurements (Tewameter TM300 or TM330T; Courage + Khazaka, Köln, [LOCATION_013]) 
 
TEWL, the passive transfer of water through the stratum corneum , will be measured for each wound site 
at Visit 2 Baseline/Pre-Wound time point, Visit [ADDRESS_1221168]-Wound ti me point, and Visits 3-16 using the 
Tewameter TM300 or TM330T (Courage + Khazaka electronic GmbH, K öln, [LOCATION_013]).  The same 
instrument (Tewameter TM300 or TM330T) that is used at Day [ADDRESS_1221169] will be used for all 
subsequent measurements.   
The measurement of water evaporation is based on the diffusion principle in an open chamber and the 
density gradient is measured indirectly by [CONTACT_874453]. 
Data are analyzed by a microprocessor and reported in g/m
2/h. A decrease in TEWL values reflects a 
decrease in the rate of water loss of the skin.  
 
Duplicate 30-second measurements will be taken for each wound s ite; if the TEWL reading is not stable 
within 30 seconds, the measurement should be expanded to 60 sec onds. A sterile metal adaptor ring (C+K 
Catalog # Z00812) will be mounted on the measuring head of the probe.  The metal adaptor ring will be 
cleaned with an ethanol wipe between wound sites on the same su bject and allowed to completely air 
dry before each reading. The metal adaptor rings will be thorou ghly cleaned and autoclaved between 
subjects.  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 35 / [ADDRESS_1221170] COMPLETION/WITHDRAWAL 
 
7.6.1. Subject Completion  
Subjects are considered to have completed the study when all st udy procedures have been completed as 
designated by [CONTACT_760]. Completion should be noted on the S creening and Enrollment Log (or 
equivalent).  7.6.2. Subject Discontinuation  When an individual who has signed the ICD is not included in th e study or discontinues/is discontinued 
prior to completing the study, the reason is to be documented o n the Screening and Enrollment Log (or 
equivalent) and in the final study report. Reasons for subject discontinuation may include: 
 
x Screen Failure (i.e. fails to meet inclusion/exclusion criteria  or chooses not to participate)  
x Participant is determined to be ineligible after enrollment 
x Subject’s choice to withdraw 
x Investigator terminated (e.g. noncompliance, etc.) 
x AE/SAE (must be reported in accordance with the reporting requi rements defined in the AE/SAE 
section “Adverse Event Reporting”). 
x Lost to follow-up 
x Protocol Violation 
x Lack of efficacy 
x Study terminated by [CONTACT_3211] 
x Death 
x Pregnancy 
x Other 
 
Subjects may withdraw from the trial at any time at their reque st, or they may be withdrawn at any time 
at the discretion of the Sponsor, PI, or designee for safety, b ehavioral, or administrative reasons. If a 
subject does not return for a scheduled visit, at least [ADDRESS_1221171] withdrawal. 
 8. STATISTICAL ANALYSIS METHODS  The analyses will be based on the Intent-to-Treat (ITT) princip le, i.e., all subjects who received laser-
induced wounds and started the study treatments will be include d in the analysis. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 36 / [ADDRESS_1221172] deviation, median, minimum a nd maximum values. Distributions of 
categorical variables will be summarized by [CONTACT_874454]. 
 8.3. ENDPOINTS 
8.3.1. Primary Endpoints 
 The primary endpoint of the study will be “Time to Complete Hea ling” defined as the time (in days) elapsed 
from the time of wound creation to 12 PM of the day on which th e composite healing score (calculated 
from the clinical grading of wound healing parameters, as defin ed below) first meets the complete healing 
criterion of being at least a score of 8. If a composite healin g score does not meet the complete healing 
criterion by [CONTACT_2006] 16, the time to complete healing will be censo red at the last day on which the composite 
healing score is available. 
 
The composite healing score will be calculated from the clinica l grading of wound healing parameters as 
follows: 
Composite Healing Score = [general wound appearance score + smo othness score + epi[INVESTIGATOR_874420]] – [erythema score + edema score + crusting/sc abbing score] 
 The composite healing score on a 25-point scale (-12 thru +12) is indicative of the extent of wound healing 
and will be calculated for each  wound site at each evaluation d ay. 
 
Time to complete healing will be analyzed using a survival anal ysis method. The survival function 
(cumulative percentage of wounds healed at each time point) wil l be estimated by [CONTACT_8761]-Meier 
method for each treatment separately. The median time to comple te healing will be derived from the 
estimated survival functions and be compared using the bootstra p re-sampling method. 
8.3.2. Secondary Endpoints 
 The secondary endpoints for this study are the change from base line* to each applicable time point (see 
Table 2) for the following parameters:   
x Change from baseline* to each app licable time point (see Table 2) for the following parameters:   
o TEWL measurements 
o Clinical Grading of Wound Healing – Erythema 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 37 / 75   o Clinical Grading of Wound Healing – Edema   
o Subject self-assessment questions 1, 3, and 5. 
o Composite Scar Score – calculated as the sum of the individual parameters on the 
Manchester Scar Scale (Color, Finish, Contour, Distortion and Texture).  Composite Scare 
Scores range from [ADDRESS_1221173] self-assessment questions 2 and 4 at each applicable ti me point. 
 *Baseline is considered the Day [ADDRESS_1221174] analysis of 
covariance (ANCOVA) model. The ANCOVA model will include the treatment as the factor and the baseline value as the covariate. The model will include subject as a ran dom effect to incorporate the within-subject 
correlation.  Self-assessment questions [ADDRESS_1221175] number .  The number of subjects experiencing AEs 
will be presented by [CONTACT_6764], preferred term, and treatment  (if assessed as related to a particular 
IP).  The latest version of the Medical Dictionary for Regulato ry Activities (MedDRA) will be used as the 
adverse event classification system.     
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 38 / 75   9. SUCCESS CRITERIA 
 
 
 
 
 
10. MANAGEMENT OF INTERCURRENT EVENTS  10.1. AMENDMENTS TO THE PROTOCOL  Neither the PI/Site nor the Sponsor will modify this protocol without obtaining the agreement of the other.   
Amendments must be approved by [CONTACT_574663]/IEC prior to implementation. 
 
The only circumstance in which an amendment may be initiated pr ior to IRB/IEC approval is where the 
change is necessary to eliminate apparent immediate hazards to the subjects. In that event, the PI [INVESTIGATOR_736626]/IEC and the Sponsor in writing within [ADDRESS_1221176] be 
captured on the Protocol Deviation Log (or equivalent).  
If a significant deviation occurs, the PI [INVESTIGATOR_874421] (see contact [CONTACT_874455]) . Contact [CONTACT_874456].  If it is det ermined that a subject’s safety/well-being was 
affected, the IRB/IEC will also be notified, as applicable.  Th e final study report will describe any deviation 
from the protocol and the circumstances requiring it. 
 10.3. ADVERSE EVENT REPORTING 
10.3.1. Introduction 
 Timely, accurate, and complete reporting and analysis of safety  information from clinical studies are 
crucial for the protection of subjects, investigators, and the Sponsor, and are mandated by [CONTACT_8125]. The Sponsor has established procedures in c onformity with regulatory requirements 
to ensure appropriate reporting of safety information.  
 
10.3.2. Definitions  [IP_ADDRESS]. Adverse Event (AE)  An AE is any untoward medical occurrence in a clinical study su bject temporally associated with the clinical 
investigation, whether or not the  event has a causal relationsh ip to the subject’s participation in the trial. 
It is therefore any unfavorable a nd unintended sign (including an abnormal finding), symptom, or disease 
that occurs during the trial. This can include any occurrence t hat is new in onset, an aggravation of 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 39 / 75   severity/frequency of a baseline condition, or abnormal results  of diagnostic procedures, including 
laboratory test abnormalities. 
 Examples of AEs include but are not limited to: 
x Abnormal test findings, 
x Clinically important symptoms and signs, 
x Changes in physical examination findings, 
x Hypersensitivity, and 
x Progression/worsening of underlying disease. 
 
Any change in existing medical condition (medical history) may be considered an AE and recorded 
appropriately.  
Additionally, they may include the signs or symptoms resulting from: 
x Product overdose, 
x Product withdrawal, 
x Product abuse, 
x Product misuse, 
x Product interactions, 
x Medication errors, 
x Product dependency, 
x Exposure in utero (EIU), and 
x Study related procedures. 
 
The criteria for determining whether an abnormal objective test  finding should be reported as an AE are 
as follows: 
x Test result is associated with accompanying symptoms, and/or 
x Test result requires additional diagnostic testing or medical/s urgical intervention, and/or 
x Test result leads to a disconti nuation from the study, signific ant additional concomitant 
treatment, or other therapy, and/or  
x Test result is considered to be an AE by [CONTACT_874457]. 
 
Merely repeating an abnormal test, in the absence of any of the  above conditions, does not constitute an 
AE. Any abnormal test result that is determined to be an error does not require reporting as an AE. 
 Expected Events 
 
Expected mild reactions (e.g. bleeding, pain, itching, etc.) re lated to the laser wounding procedure, normal 
healing process, and IP removal will not be captured as AEs unl ess there is exacerbation (moderate or 
severe) of these reactions as judged by [CONTACT_978] [INVESTIGATOR_1461]. All  reactions will be documented in the source 
documents.   
Pre-Treatment AE (PTAE) 
 
A PTAE is defined as any AE present prior to the initiation of the treatment/administration of IP. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 40 / 75   [IP_ADDRESS]. Serious Adverse Event (SAE) 
 
An AE (untoward medical occurrence) will be considered an SAE i f it meets either of the following 
definitions: 
Definition 1:   
 The event fulfills at least one of the following criteria: 
x Results in death 
x Is life-threatening (immediate risk of death) 
x Requires inpatient hospi[INVESTIGATOR_5186] n or prolongation of existing hospi[INVESTIGATOR_059]  
x Results in a persistent or significant incapacity or substantia l disruption of the ability to conduct 
normal life functions 
x Is a congenital anomaly/birth defect 
x Is considered a medically significant event (medical and scient ific judgment
should be exercised in 
deciding whether expedited reporting is appropriate in other situations, such as important medical 
events that may not result in death, be life-threatening, or require hospit alization but may be 
considered a serious adverse drug experience when, based upon a ppropriate medical judgment, 
they may jeopardize the patient or subject and may require medi cal or surgical intervention to 
prevent one of the other outcomes listed above. Examples of suc h medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room  or at home, blood dyscrasia, 
or convulsions that do not result in hospi[INVESTIGATOR_059]; or develo pment of drug dependency or drug 
abuse, or malignancy) 
x Is a suspected transmission of any infectious agent via a produ ct (medically significant) 
Definition 2:   
 
x the event involves subject contact [CONTACT_4490] a device AND 
x the event results in: 
o Death 
o Serious injury, which means a n injury or illness that: 
 Is life-threatening (immediate risk of death) 
 Results in permanent impairment of a body function or permanent  damage to a 
body structure, or 
 Necessitates medical or surgical intervention to preclude perma nent impairment 
of a body function or permanen t damage to a body structure ( permanent means 
irreversible impairment or damage to a body structure or functi on, excluding 
trivial impairment or damage ). 
o Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
o A malfunction that the device (or similar device marketed by [CONTACT_3433] e same manufacturer or 
importer) would be likely to cause death or similar injury if t he malfunction were to recur. 
o Any suspected transmission of any infectious agent via a produc t (medically significant). 
 [IP_ADDRESS]. Severity 
 
The severity of all AEs must be assessed by [CONTACT_38234] .  
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 41 / 75   The severity classifications are: 
x Severe  – Extreme distress, causing significant impairment of function ing or incapacitation; 
interferes significantly with subject's usual function; prevent s normal everyday activities. 
x Moderate  – Sufficient discomfort is present to cause interference to so me extent with subject's 
usual function or normal everyday activity.  
x Mild – Awareness of symptoms that are easily tolerated, causing mini m a l  d i s c o m f o r t  a n d  n o t  
interfering with subject's usual function or normal everyday ac tivities. 
 Note the distinction between the severity and the seriousness o f an AE. A severe event is not necessarily 
a serious event. For example, a headache may be severe (interfe res significantly with subject's usual 
function) but would not be classified as serious unless it met one of the criteria for SAEs, listed above. 
 
[IP_ADDRESS]. Causality Assessment 
 
An AE (serious or non-serious) is considered “study-related” if  the causality assessment is possible, 
probable, or very likely.  The Study Physician  determines the causality by [INVESTIGATOR_1477]: 
 
x Not related  – an AE that is not related to the participation in the study.  
x Doubtful  – an AE for which an alternate explanation is more likely (e.g . concomitant drug), or the 
relationship in time suggests that a causal relationship is unl ikely. 
x Possible  – an AE that might be a result of participation in the study. An alternative explanation is 
inconclusive and the relationship in time is reasonable so a ca usal relationship cannot be 
excluded. 
x Probable  – an AE that might be a result of participation in the study. The relationship in time is 
suggestive (e.g. confirmed by [CONTACT_515180]). An alternative ex planation is less likely. 
x Very Likely  – an AE that is listed as a possible adverse reaction and cann ot be reasonably explained 
by [CONTACT_4867]. The relationship in time is very  suggestive (e.g. confirmed by 
[CONTACT_35719]). 
 10.3.3. Procedures for Reporting AEs  All AEs will be reported from the time a signed and dated ICD i s obtained until completion of the subject’s 
last study procedure or visit (or termination if the subject te rminates early from the study for any reason). 
 
AEs that occur within 30 calendar days after completion of the study will only be reported to the Sponsor 
if they are serious (i.e. SAEs). SAEs are reportable beyond thi s period if the event is considered study-
related. The Sponsor will evaluate any safety information that is spontaneously reported by [CONTACT_978]/Site 
beyond this time frame. 
 
Subjects are encouraged to report AEs spontaneously and in resp onse to questioning during the visit (e.g. 
if they have had any side effects/issues or changes in their he alth since their last appointment). For each 
AE reported by [CONTACT_874458], the Si te team member should notify the PI [INVESTIGATOR_126985], who will collect information about the event.  
All AEs, regardless of seriousness, severity, or presumed relat ionship to study procedures, must be 
recorded using medical terminology.  Whenever possible, diagnoses should be given when signs and 
symptoms are due to a common etiology (e.g., cough, runny nose,  sneezing, sore throat, and head 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 42 / 75   congestion should be reported as “upper respi[INVESTIGATOR_4416]”) . The Study Physician  must record or 
confirm their opi[INVESTIGATOR_874422], severity, and  relationship of the AE to the study. All 
measures required for AE management must be recorded and report ed according to Sponsor instructions. 
 
These events must then be entere d into the EDC system within 3  business days of the Site’s awareness. 
 Tabulation of AEs
  
 AEs will be reported in a table detailing the different AE type s highlighted in this protocol: 
x Pre-Treatment AEs (PTAEs) 
x Expected AEs  
x AEs related to the product(s)/study 
x AEs not related to the product(s)/study 
x SAEs related to the product(s)/study 
x SAEs not related to the product(s)/study 
 
Additional Reporting Procedures 
 The PI [INVESTIGATOR_874423]/ IEC unless otherwise required and 
documented by [CONTACT_1201]/IEC.   If a SAE occurs, in addition to the above reporting procedures, the Site  will immediately  upon SAE 
awareness notify the SM or designee by [CONTACT_515184] e mail (see contact [CONTACT_874459]).   
Subsequent to a telephone or encrypted email report of an SAE  and within 24 hours of awareness  of the 
SAE, the Site will complete and securely send (MBOX, Cisco, Secure  mail) the Clinical Investigation SAE 
Report Form signed by [CONTACT_874460], 
including: 
x The Study Physician’s  assessment of causality  
x The subject identification number, the identity of SAE reporter , the IP/auxiliary product 
information (if applicable), the SAE description/outcome 
x Any relevant supporting documentation (e.g., medical history, c oncomitant medications). Note 
that if relevant supporting documentation requires translation,  these translations must be sent 
securely  within 3 business days after initial notification.  
This above process also applies to additional new information ( follow-up) on previously forwarded SAE 
reports.  
 
The PI [INVESTIGATOR_874424]-up information or more 
detailed information in an expedited fashion. In general, this will include a description of the SAE in 
sufficient detail to allow for a complete medical assessment of  the case and independent determination 
of possible causality.  Information on other possible causes of  the event, such as concomitant medications 
and illnesses, must be provided.  
 
In the case of a subject death, a summary of autopsy findings ( if available) and death certificate should be 
collected if permission is obtained from the subject’s family.  
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 43 / 75    
For a hospi[INVESTIGATOR_059], a copy of the hospi[INVESTIGATOR_874425]. If obtained, these 
documents (with subject’s personal identifiers redacted) should  be securely submitted as soon as possible 
to the SM or designee. 
 
All the documentation pertaining to the SAE will be filed in th e SMF. 
 10.3.4. Monitoring and Resolution of AEs  [IP_ADDRESS]. Non-Serious AEs  All study-related AEs will be followed until resolution, until a stable clinical endpoint is reached, or at least 
[ADDRESS_1221177]-study withdrawal/completion. This information will  be captured and entered into the  EDC 
system. 
 
[IP_ADDRESS]. Serious AEs (SAEs)  All SAEs will be followed by [CONTACT_874461] (“Resolution”) is met. This information will be capture d and entered into the EDC system.  The 
PI/designee will also document follow-up information on an upda ted Clinical Investigation SAE Report 
Form, which will be reviewed by [CONTACT_874462].  [IP_ADDRESS]. Resolution 
 
The Study Physician will be req uired to assess the outcome of e ach AE as one of the following:  
x Resolved 
x Not Resolved 
x Fatal 
x Resolved with sequelae 
x Resolving 
x Unknown 
 
SAEs that have not been resolved by [CONTACT_2054], or th at have not been resolved upon 
discontinuation of the subject’s participation in the study, mu st be followed until any of the following 
occurs:  
 
x the event resolves 
x the event stabilizes 
x the event returns to baseline, if a baseline value is available  
x the event can be attributed to factors unrelated to study condu ct 
x when it becomes unlikely that any additional information can be  obtained (subject or healthcare 
practitioner refusal to provide additional information; lost to  follow-up after demonstration of 
due diligence with follow-up efforts). 
 
 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 44 / 75   10.3.5. Pregnancy Reporting and Exposure In Utero (EIU) 
 
Pregnancy in a female study subject is reportable to the Sponso r. Pregnancies will be reported from the 
time a signed and dated ICD is obtained until completion of the  s u b j e c t ’ s  l a s t  s t u d y  p r o c e d u r e  ( o r  
termination if the subject terminates early from the study for any reason). Pregnancies that occur 
between the subject’s last visit and [ADDRESS_1221178] been  EIU (according to date of last  menses). 
 Pregnancies occurring in subjects classified as screen failures  do not require follow-up unless the 
screening procedures could have had an effect on the pregnancy outcome or the screen failure was 
detected after the study procedures or application/use of the i nvestigational study material(s) was already 
started.   
Follow-up on pregnancy data (e.g., outcome of pregnancy) must o ccur regardless of whether or not the 
subject remains in the study. The PI [INVESTIGATOR_486891]-up  the pregnancy until its successful 
completion or early termination ( i.e. abortion) and then notify  the Sponsor of the outcome. 
 If a reportable pregnancy/EIU occu rs, the PI [INVESTIGATOR_502209]: 
x For initial notification, complete and send securely the “ Pregnancy Notification and Update Form ” 
to the SM or designee within 24 hours of awareness. 
x Provide any updates using the “ Pregnancy Notification and Update Form.”  
x Follow-up with the subject to determine the pregnancy outcome. At the end of the pregnancy, 
complete and send securely the “ End of Pregnancy Collection Form ” within 24 hours from when 
the information becomes available. 
 The PI [INVESTIGATOR_874426] S AEs if the outcome of the pregnancy meets 
the criteria for immediate classification as a SAE, such as spo ntaneous abortion, stillbirth, neonatal death, 
congenital anomaly (including that in an aborted fetus, stillbi rth, or neonatal death), or any infant death 
that the Study Physician  assesses as possibly related to EIU. 
 
In the case of a live birth, the viability of the newborn will be assessed at the time of birth; no minimum 
follow-up period of a presumably  normal infant is required befo re an “ End of Pregnancy Collection Form ” 
can be completed.  All the documentation pertaining to the pregnancy will be filed  in the SMF. 
 11. ETHICAL CONSIDERATIONS  
11.1. SUBMISSION TO INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHI CS COMMITTEE 
 
This study (protocol, ICD, recruiting material [advertisements,  phone script, etc.], and all addenda) will be 
reviewed and approved by [CONTACT_2717]/IEC contact[CONTACT_874463] .  
 Details of the IRB/IEC for this study are located in Appendix V II. 
 It is the responsibility of the PI [INVESTIGATOR_874427]/IEC approval of the study protocol, protocol amendments, 
ICD(s), and other relevant documents, e.g., advertisements, as applicable.  
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 45 / 75   The study will not be activated and subjects will not be recrui ted, consented, or receive study materials 
until such time as the IRB/IEC has approved the required docume ntation. In addition, the IRB/IEC will 
review the study before any significant change in the protocol is initiated. After each review, the IRB/IEC’s 
approval letter will be forwarded to the Sponsor. All correspon dence with the IRB/IEC should be retained 
in the SMF.  
 12. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_874428]’s subject records and  are to be maintained at the Study Site. 
The study source documents must be attributable, legible, conte mporaneous, original, accurate, and 
complete, and must collect only relevant data required by [CONTACT_3181]. All documentation should be 
completed using good documentation  and data integrity practices . 
 
The following source data will be captured on paper source docu ments: 
x ICD, HIPAA Disclosure, and Photograph Release 
x Inclusion/Exclusion Criteria 
x BMI 
x Medical History 
x Concomitant Medications 
x Investigational Study Material s Accountability Information 
x Protocol Deviations  
 
Subject self-assessment questionnaires will be completed using Qualtrics (Provo, UT), an online survey 
platform. If needed, subjects may complete these questionnaires  on paper and the Site will enter the 
information into Qualtrics or Medidata Rave. 
 
The following data will be captured directly in the Sponsor’s E DC system: 
x Demographics 
x Fitzpatrick Skin Type Classification 
x Randomization 
x Clinical Grading of Wound Healing Parameters 
o Erythema score 
o Edema score 
o Epi[INVESTIGATOR_874429] 
o Crusting/scabbing score 
o Smoothness score 
o General wound appearance score 
x Manchester Scar Scale 
o Color score 
o Finish (matte versus shiny) score 
o Contour score 
o Distortion score 
o 
Texture score 
x TEWL Measurements 
x Adverse Events 
x Subject Disposition 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 46 / [ADDRESS_1221179] parties, except for 
authorized representatives of the Sponsor or appropriate regula tory authorities, without written 
permission from the Sponsor.  It is the PI’s responsibility to ensure completion and to revie w and approve all information captured in the 
EDC system. The subject’s data in the EDC system must be electr onically signed by [CONTACT_978]. These signatures 
serve to attest that the information contained in the EDC syste m is true. At all times, the PI [INVESTIGATOR_874430] l clinical data entered in the EDC system. 
 
The Sponsor or its designee will have responsibility for verify ing for accuracy of the data entered into the 
EDC system against the source documents (as applicable). 
 All data entered into the EDC system and Qualtrics will be sent  to the Sponsor’s Quantitative Sciences 
Department for statistical analysis.  All final data recorded i n the EDC system will be kept by [CONTACT_874464].   The Study Site shall maintain an d archive the SMF for [ADDRESS_1221180], even if retention requ irements are 
met. 
 
If it becomes necessary for the Sponsor or a Regulatory Authori ty to review any documentation relating 
to the study, the PI/Site must permit access to such records.  
 If the PI [INVESTIGATOR_283236], retires, or for any reason withdraws from the study, the Sponsor must be prospectively 
notified.  13. STUDY MONITORING, QUALITY CONTROL, AND QUALITY ASSURANCE  The study will be monitored by [CONTACT_19489] a  site or study-specific monitoring plan. 
Frequent communications (via telephone or email) will be utiliz ed to provide Sponsor oversight and to 
assist in resolving any difficulties encountered while the stud y is in progress. Monitoring visits may occur 
during the study or after study completion to ensure that the i nvestigation is/was conducted according to 
the protocol and that the principles of ICH GCP are/were being followed. The monitors may review study 
documents to confirm that the data recorded is complete and acc urate. 
 The PI/Site will allow the Sponsor’s monitors or its representa tives and appropriate regulatory authorities 
direct access to study documents to perform monitoring. If ther e are any issues noted, the PI [INVESTIGATOR_650647].  
Any contact [CONTACT_874465]  (see contact [CONTACT_874466]). 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 47 / [ADDRESS_1221181] to review by [CONTACT_1201]/IEC (if applicable), to quality assurance audits 
performed by [CONTACT_1034], and/or to inspection by [CONTACT_90646] r egulatory authorities. 
 
It is important that the PI [INVESTIGATOR_874431]. 
 14. SPONSOR DISCONTINUATION CRITERIA  Premature termination of this clinical trial may occur because of a change in opi[INVESTIGATOR_1100]/IEC, IP or 
study safety problems, or at the discretion of the Sponsor. If a trial is prematurely terminated or 
discontinued, the Sponsor will promptly notify the PI/Site. Aft er notification, the PI [INVESTIGATOR_874432] 10 business days  (phone, voicemail, or certified letter), as 
applicable. As directed by [CONTACT_941] S ponsor, all trial materials mus t be collected, all documents completed to 
the greatest extent possible, and termination reported to the I RB/IEC. 
 15. FINAL REPORT  The draft report will be prepared by [CONTACT_19617] J. Stephens and Ass ociates. 
 The draft report will be submitted to the Sponsor for review an d changes may be made to the draft report 
at the Sponsor’s request. Upon Sponsor’s/study team’s approval, the report will be finalized and forwarded to the Sponsor. The final report will include (but is  not limited to) the following information: 
study design and protocol, subject population demographics, sta tistical methods used, results, description 
of AEs (if any), protocol deviations, discussions, and conclusi ons.  
 
 
  
 
 
16. CONFIDENTIALITY 
 All of the subjects’ private information, the data, and the stu dy results are confidential. This information 
will only be made available to th e study team, authorized Spons or personnel or designees, and authorized 
external personnel and the data will be managed according to th e local Data Privacy requirements and 
regulations.  17. PUBLICATION 
 
The publication agreement, if any, between the Sponsor and the site is detailed in the clinical trial 
agreement.        
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 48 / 75   18. BIBLIOGRAPHIC REFERENCES 
 
1) Mancini AJ, Sookdeo-Drost S, Madison KC, Smoller BR, Lane AT . Semipermeable dressings 
improve epi[INVESTIGATOR_874433]. Pediat r Res., 36(3):306-14, 1994.  
 
2) Winter GD. Formation of the scab and the rate of epi[INVESTIGATOR_874434]. Nature. 193:293-4, 1962. 
 
3) Winter G.D. Some factors affecting skin and wound healing. J Ti ssue Viability. 16(2):20-3, 2006.  
 4) Trookman NS, Rizer RL, Weber T. Treatment of minor wounds fr om dermatologic procedures: a 
comparison of three topi[INVESTIGATOR_804971] a laser wound model. J Am Acad 
Dermatol., 64([ADDRESS_1221182]): S8-15, 2011.  
 
5) Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar  scales and scar measuring devices. 
Eplasty, 10: e43, 2010. 
  
6) NIH Publication No. 98-4083 ( 1998, September). Adapted from Clinical Guidelines on the 
Identification, Evaluation, and Treatment of Overweight and Obe sity in Adults: The Evidence 
Report. Retrieved from URL. https://www.nhlbi.nih.gov/health/e ducational/lose_wt/BMI/bmi_tb l.htm. 22 May 2019. 
 7) Easy.Ink™ Semi-Permanent Tattoo Freehand Ink – Full Kit.  20 19.  Retrieved from 
https://easy.ink/collections/freehand-ink/products/freehand-ink -full-kit. 
 
8) Buckenmaier CC, Galloway KT, Polomano RC, McDuffie M, Kwon N , Gallagher RM. Preliminary 
validation of the Defense and Veterans Pain Rating Scale (DVPRS ) in a military population.  Pain 
Medicine, 14(1):110-23, 2013. 
 
 [Remainder of Page Intentionally Left Blank] 
    
 
   
 
     
 
 
 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 49 / 75   19. PROTOCOL SIGNATURE [CONTACT_874472]: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 50 / [ADDRESS_1221183] read and understood this study protocol, attached append ices, and any amendments and/or 
supplements thereto. 
 
I agree to conduct the study in compliance with this protocol a nd in accordance with U.S. Food and Drug 
Administration (FDA) regulations, applicable local regulations, and the principles of ICH GCP as outlined herein.   Furthermore, I agree to make no additions and/or changes withou t the consent of the Sponsor, except 
when necessary to protect the safety of the subjects.   I will provide copi[INVESTIGATOR_874435]. I wi ll discuss this material with them to ensure 
that they are fully informed regarding the protocol and conduct  of this study.  
 I undertake the responsibility of promptly communicating to the  IRB/IEC or other applicable Institution 
and to the Sponsor any complications that may occur during the cour se of the study. 
 I further undertake the responsibility of following up on all t he measures required to ensure the safety 
and the rights of the subjects.   Signature [CONTACT_50858]: 
 
  
 
  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 51 / 75   21. APPENDICES 
 
Appendix I.  Fitzpatrick Sk in Type Classification ............. ............................................................... ...... 52 
Appendix II. Body Mass Index Table6 .............................................................. .................................... 53 
Appendix III. Subjec t Instructions ............................ ............................................................... .............. 54 
Appendix IV. Ingredient Listing ............................... ............................................................... ............... 55 
Appendix V. Temporary (Semi-Permanent) Dot-Tattoo Procedure7 ................................................... [ADDRESS_1221184] Self-Assessment Questionnaire (Day 0 throu gh Day 4) ..................................... [ADDRESS_1221185] Information ............................. ............................................................... ............ 58 
Appendix VIII.   S ummary of Changes – Amendment 1 ............. .............................................................. 60 
Appendix IX.   Summary of C hanges – Amendment 2 ............... ............................................................ 64  
Appendix X.   Summary of C hanges – Amendment 3 ................ ........................................................... 72 
 
 
    
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 52 / [ADDRESS_1221186] 30 to 45 
minutes of sun exposure after a winter season without sun expos ure.  The categories of skin types are as 
follows: 
    
 
    
 
This study will only be enrolling Fitzpatrick Skin Types II – I II. 
  Skin 
Type  Characteristics  
I Always burns easily, never tans (sensitive) 
II Always burns easily, tans minimally (sensitive)  
III Burns moderately, tans gradua lly (light brown) (normal)  
IV Burns minimally, always tans we ll (moderate brown) (normal) 
V Rarely burns, tans profusely (dark brown) (insensitive) 
VI Never burns, deeply pi[INVESTIGATOR_49194] (insensitive) 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 53 / 75   Appendix II. Body Mass Index Table6 
 
 
 
   
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 54 / [ADDRESS_1221187] Instructions 
 
During the study, please follow the instructions below:  
x Use the provided cleanser on your forearms and body for the dur ation of the study in place of 
your normal body cleanser. Do not use any other products on you r forearms during the study.  
For the rest of the body, continue using your normal skincare p roducts; do not start using any 
new products/brands.  
x Do not wet or put your forearms in water for the duration of th e study (i.e., swimming, baths, hot 
tubs, etc.). Only showering is acceptable. 
x Do not shower within [ADDRESS_1221188] sites to sunlight or use tanning booths/ beds during the study. 
x Wear long sleeves when going outdoors and for the first 12 hour s after each tattoo application 
(ink may transfer to other skin locations). 
x Avoid touching/scratching the test sites. 
x Leave the test products (the bandages) on your forearms – only the study site should remove or 
apply them.  If the bandages become loose between clinic visits , you may use the provided tape 
to secure the bandage; apply the tape only on the adhesive part s of the bandage (not on the pad 
or middle of the bandage). 
x If any test product (bandage) falls off, record the date and ti me that the bandage fell off and 
report that information at your next visit. Do not try to reapp ly any bandage if it falls off. Please 
bring the bandage that has fallen off to your next visit. 
x Whenever possible, inform the study team before you start using  any new medication.  
x Avoid pregnancy by [CONTACT_874446] a medically acceptable con traception method, if applicable. 
x Attend all study visits at the scheduled time and date. 
x Do not start any other studies during this study. 
   
 
        
 
 
    
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 55 / 75    
Appendix IV. Ingredient Listing 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
        
 
   
 
     
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 56 / 75   Appendix V. Temporary (Semi-Permanent) Dot-Tattoo Procedure7 
 
How to Apply: 
 
1) Wear gloves throughout the dot-tattoo procedure. 
2) Shake the bottle to make sure the ink is uniformly mixed. 
3) Unscrew lid to ink bottle and place tip on bottle. 
4) Squeeze out a small amount of in k onto a paper towel to get the  air out of the tip.  (Wipe the tip 
regularly to keep it clean and avoid clogging). 
5) Squeeze a small amount of ink (~1mm thick) onto the desired loc ation (a template may be 
used).   
a. First application:   apply dot-tattoos to the skin a djacent to the wound sites (id eally 
equidistant between the wound sites).  The tattoos must be   
 but s hould be placed so as not to i nterfere with evaluations. 
b. Subsequent applications:   apply dot-tattoos to the skin adjacent to the previous dot-
tattoos (e.g. may alternate between two locations for each woun d site).  In all instances, 
the tattoos   but should be 
placed so as not to interfere with evaluations.  
6) Let ink sit on skin for a minimum of 30 minutes.  Note:  the ta ttoo will not be visible for a few 
hours once the ink is removed, so all evaluations should be com plete prior to ink removal 
(especially at Visit 2 [Baseline]) to ensure consistent identif ication of wound sites and visibility of 
tattoos  
7) Use a moist paper towel to carefully remove ink once all evalua tions are complete. 
8) Tattoo will appear a few hours after ink removal. 
9) Subjects should be reminded to wear long sleeves for 12 hours a fter tattoo applications to 
prevent transfer of ink to other skin locations. 
 
Storage:   Refer to package instructions. 
  
 
 
 
 
 
 
 
 
  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 57 / [ADDRESS_1221189] Self-Assessment Questionnaire (Day 0 throu gh Day 4) 
 
<Additional Day 0 Instructions: Please complete this questionnaire as soon as the numbness is g one (this 
will be around 3-4 hours after the numbing cream was applied).>  
 
Please answer the following questions for each wound on your fo rearms.  Focus on each wound itself (not 
the surrounding skin that might al so be covered by a bandage).  The wound sites are numbered as shown 
in Pi[INVESTIGATOR_1103] 1.  Some of the questions will use the scale in Pi[INVESTIGATOR_648130] 2. 
    Pi[INVESTIGATOR_1103] 1. Wound Site Numbering                   Pi[INVESTIGATOR_1103] 2. Sc ale for Answering Questions 1, 3, and 5 
 
Note: If you cannot provide an answer for a specific wound site  because you cannot distinguish the 
pain/itch sensation from neighboring wounds, choose “Cannot Dis tinguish” or enter an X. 
 
 
 Wound Site (see Pi[INVESTIGATOR_1103] 1 above) 
Question 1 2 3 4 5 6 7 8 
1) With your arm resting by [CONTACT_874467], how painful/sore is each wound site? Use the scale in Pi[INVESTIGATOR_1103] 2.         
2 )  I s  t h e  p a i n  ( d e s c r i b e d  i n  # 1 )  b r i e f  ( B) ,  p e r i o d i c  ( P), or 
constant ( C)?         
3) With your arm in normal motion, how painful/sore is each wound site? Use the scale in Pi[INVESTIGATOR_1103] 2.         
4) Is the pain (described in #3) brief ( B) ,  p e r i o d i c  ( P), or 
constant ( C)?         
5) How itchy is each wound site? Use the scale in Pi[INVESTIGATOR_1103] 2.         
 
[ADDRESS_1221190] KT, Polomano RC, McDuffie M, Kwon N, G allagher RM. Preliminary validation of the Defense and Veterans  Pain Rating 
Scale (DVPRS) in a military pop ulation.  Pain Medicine. 2013 Ja n 1;14(1):110-23. 
 
 
  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 58 / [ADDRESS_1221191] Information 
 
SPONSOR:  [COMPANY_012] Consumer Inc. 
[ADDRESS_1221192]  
Skillman, NJ [ZIP_CODE]  
 
STUDY SITE:   
Tho
mas J. Stephens & Associates, Inc.  
Dallas  Research Center 
[ADDRESS_1221193]., Suite 200  
Richardson, [LOCATION_007] [ZIP_CODE] [LOCATION_003]  
 
 
STUDY MANAGER:   
   
  
 
STUDY DIRECTOR:  Robin Mathew, Ph.D.  
Address:  Refer to Sponsor address    
  
 
DEPARTMENT HEAD:    
   
    
 
HEAD OF CLINICAL RESEARCH:   
   
  
 
DESIGNATED PHYSICIAN 
REPRESENTATIVE:  
 
 STATISTICIAN:
 
 
  STUDY MONITIOR:
 
 
   
 
 
 
  
 
 
 
PRINCIPAL INVESTIGATOR: [INVESTIGATOR_874436], Ph.D. 
[ADDRESS_1221194]., Suite 20 0, Richardson, [LOCATION_007] [ZIP_CODE] [LOCATION_003] 
  
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 59 / 75   STUDY PHYSICIAN: 
 
  
SUB
-INVESTIGATOR:   
   
 
 
 
  
 
IRB/IEC:  
 
 
 
   
 
     
 
 
 
       
 
   
 
     
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 60 / 75    
Appendix VIII.   Summary of  Changes – Amendment [ADDRESS_1221195] Name: N/A 
Protocol Number: CCSTOH001689 
IND/IDE/Eudra CT: N/A 
Phase: N/A 
Sponsor: [COMPANY_012] Consumer, Inc. 
Version and Date  Amendment 1: Final Version 2.0, 12 Aug 2019 
Original: Final Version 1.0, 10 Jul 2019  
 
  
 
CONFIDENTIAL:  This document contains privileged and confidenti al information belonging to the 
Sponsor.  Except as otherwise agreed to in writing, by [CONTACT_874468] g or reviewing this document, you agree 
to hold the information contained herein in confidence and not copy or disclose it to others (except where 
required by [CONTACT_1289]) or use it for unauthorized purposes . In the event information is disclosed to 
others, as required by [CONTACT_1289], they must be informed th at the information is privileged and 
confidential and may not be further disclosed by [CONTACT_476]. These re strictions on disclosures will apply equally 
to all future information supplied to you that is indicated as privileged and confidential. You agree that no 
unpublished information contained herein will be published or d isclosed without the prior written approval 
of Sponsor. In the event of any actual or suspected breach of t his obligation, Sponsor must be promptly 
notified. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 61 / 75   1. REASONS FOR THE AMENDMENT TO THE FINAL PROTOCOL 
 
Sections of protocol CCSTOH001689 , “A 28-Day, Single Center, Randomized, Comparator-
Controlled, Proof-of-Principle Study to Assess Wound Healing Ef ficacies of Different Adhesive 
Bandages ”, dated J uly 10, 2019 (Final Version 1.0), have been revised to change t he type of 
reinforcement tape used, correct SAE definition 2, correct ques tion #[ADDRESS_1221196] Screen Fail ure language, and clarify a few 
procedures in section 7 to match the Schedule of Events in Tabl e 2. 
 2. PROTOCOL SECTIONS REVISED 
 The protocol sections that were revised are detailed below. The  format is as follows: 
 
x The “Deleted” section represents the original text in Protocol # CCS TOH001689, 
Final Version 1.0, dated July 10, 2019, that was deleted for Fi nal Version 2.0, dated 
August 12, 2019. 
x The “Changed From” section represents original text in Protocol  # CCSTOH001689, 
Final Version 1.0, dated July 10, 2019, that was changed to new  text in Final Version 
2.0, dated August 12, 201 9. The revised text is indicated in the “Changed To” 
section. 
x The “Added” section represents new text in Protocol # CCSTOH001689, Final 
Version 2.0, dated August 12, 2019. 
 
2.1. Screen Failure (Section 4.5) 
 
Changed From: 
 
All individuals who sign the ICD and withdraw their consent  for participation in the study or fail 
to meet at least one of the eligibility criteria during the initial evaluation will be considered a “screen failure” and their data will not be considered in the f inal report (except for scr een failed 
subjects with an AE, in which case the demography, subject disp osition, and AE information 
will be entered in the Electronic Data Capture (EDC) system and  the AEs will be included in 
the final report) . 
 
Changed To: 
 All individuals who sign the ICD and withdraw their consent  for participation in the study or fail 
to meet at least one of the eligibility criteria during the initial evaluation will be considered a 
“screen failure” and their data will be entered in the Electronic Data Capture (EDC) system 
and the AEs will be included in the final report . 
 
2.2. Additional application details for all IPs (Section 6.5.2)  
 
Changed From: 
 
  
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 62 / 75   Changed To: 
 
  
 
2.3. 
Study Procedures and Evalua tion Schedule (Section 7.2, Tab le 2) 
 
Changed From: 
 
CAssessment will be completed remotely approximately 2-4 hours a fter BLT cream application 
once numbness is gone. 
 
Changed To: 
 
CAssessment will be completed remotely approximately 3-4 hours a fter BLT cream application 
once numbness is gone. 
 2.4. Self-Assessment Questi onnaire (Section [IP_ADDRESS]) 
 
Changed From: 
 
2-4 hours 
 
Changed To: 
 3-4 hours 
 
2.5. Visit 17-18 (Day 15-16) (Section 7.2.7) 
 
Changed From: 
 
x Subjects will be reminded of the study instructions. Wound sit es will remain uncovered for 
the remainder of the study.  
 Changed To: 
 
x At Visit 17: The designated IP will be applied to each test si te per the randomization 
schedule. 
x At Visit 18:  Subjects will be reminded of the study instructi ons. Wound sites will remain 
uncovered for the remainder of the study. 
 
  
 
Changed From: 
 
Visits 3-19  
Changed To: 
 
       Visits 3-20 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 63 / 75   2.7. Serious Adverse Event (SAE) Definition 2 (Section [IP_ADDRESS] ) 
 
Added:  
x A malfunction that the device (or similar device marketed by t he same manufacturer or 
importer) would be likely to cause death or similar injury if t he malfunction were to recur.   
 
Deleted: 
 
x Congenital anomaly/birth defect   
 
2.8. Subject Self-Assessment Que stionnaire (Day 0 through Day 4 ) (Appendix VI)  
 
Changed Form: 
 
<Additional Day 0 Instructions: Please complete this questionnaire as soon as the numbness 
is gone (this will be around 2-4 hours after the numbing cream was applied).> 
 
… 
 
4) is the pain (described in #4) brief ( B), periodic ( P), or constant ( C)? 
 
Changed To: 
 
<Additional Day 0 Instructions: Please complete this questionnaire as soon as the numbness 
is gone (this will be around 3-4 hours after the numbing cream was applied).> 
 
… 
 
4) Is the pain (described in #3) brief ( B), periodic ( P), or constant ( C)? 
 
   
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 64 / 75   Appendix IX.   Summary of  Changes – Amendment [ADDRESS_1221197] Name: N/A 
Protocol Number: CCSTOH001689 
IND/IDE/Eudra CT: N/A 
Phase: N/A 
Sponsor: [COMPANY_012] Consumer, Inc. 
Version and Date  Amendment 2: Final Version 3.0, 20 Aug 2019  
Amendment 1: Final Version 2.0, 12 Aug 2019 
Original: Final Version 1.0, 10 Jul 2019  
 
 
 
 
CONFIDENTIAL:  This document contains privileged and confidenti al information belonging to the 
Sponsor.  Except as otherwise ag reed to in writing, by [CONTACT_874468] g or reviewing this document, you agree 
to hold the information contained herein in confidence and not copy or disclose it to others (except where 
required by [CONTACT_1289]) or use it for unauthorized purposes . In the event information is disclosed to 
others, as required by [CONTACT_1289], they must be informed th at the information is privileged and 
confidential and may not be further disclosed by [CONTACT_476]. These re strictions on disclosures will apply equally 
to all future information supplied to you that is indicated as privileged and confidential. You agree that no 
unpublished information contained herein will be published or d isclosed without the prior written approval 
of Sponsor. In the event of any actual or suspected breach of t his obligation, Sponsor must be promptly 
notified. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 65 / 75   1. REASONS FOR THE AMENDMENT TO THE FINAL PROTOCOL 
 
Sections of protocol CCSTOH001689 , “A 28-Day, Single Center, Randomized, Comparator-
Controlled, Proof-of-Principle Study to Assess Wound Healing Ef ficacies of Different Adhesive 
Bandages ”, dated August 12, 2019 (Final Version 2.0),  
 
  
 
2. PROTOCOL SECTIONS REVISED 
 
The protocol sections that were revised are detailed below. The  format is as follows: 
 
x The “Deleted” section represents the original text in Protocol # CCS TOH001689, 
Final Version 2.0, dated August 12, 2019, that was deleted for Final Version 3.0, 
dated August 20, 2019. 
x The “Changed From” section represents original text in Protocol  # CCSTOH001689, 
Final Version 2.0, dated August 12, 2019, that was changed to new text in Final 
Version 3.0, dated August 20 , 2019. The revised text is indicated in the “Changed 
To” section.  
x The “Added” section represents new text in Protocol # CCSTOH001689, Final 
Version 3.0, dated August 20, 2019. 
 
2.1. Synopsis (Dose and Mode of Application) 
 
Added: 
 **Wound sites will remain uncovered once completely healed.  
 
2.2. Synopsis (Measurement and/or Evaluation Schedule) 
 
Changed From: 
 
The following evaluations will be conducted for each wound site  at the indicated time points: 
x Clinical Grading of Wound Healing Parameters (erythema, edema, epi[INVESTIGATOR_874395], 
crusting/scabbing, smoothness, and general wound appearance) – Day 0 through Day 16*  
x Scarring Assessment - Day 0 and Day 28 
x  
x  
x TEWL Measurements - Day 0 through Day 14* 
x   
x Self-Assessment Questionnaire - Day 0 through Day 4 
 
  
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 66 / 75   Changed To: 
 
The following evaluations will be conducted for each wound site  at the indicated time points: 
x Clinical Grading of Wound Healing Parameters (erythema, edema, epi[INVESTIGATOR_874395], 
crusting/scabbing, smoothness, and general wound appearance) – Day 0 through Day 16* (or until 
completely healed, if earlier) 
x Scarring Assessment - Day 0 and Day 28 
x  
x  
 TEWL Measurements - Day 0 through Day 14* 
x  
 
x Self-Assessment Questionnaire - Day 0 through Day 4 
 
  
 
 
2.3. Study Design (Section 3.0) 
 Changed From: 
 
 
 
 
 
 
 
Between Baseline and Day 16, each wound site will be subjected to one of eight randomly-assigned 
treatments (see section 6).  Treatments include an adhesive ban dage that is considered the  a 
marketed adhesive bandage benchmark control, a non-marketed adh esive bandage benchmark control, 
four non-marketed adhesive bandages, and no treatment (uncovere d, negative control).   
 
 
 
 
  
 
Changed To: 
 
 
 
 and TEWL (until Day 14).  In addition, subjects will a ssess the wound sites vi a questionnaire from 
Day 0 to Day 4,  
 
 
 
Between Baseline and Day 16, each wound site will be subjected to one of eight randomly-assigned 
treatments (see section 6) until day of complete healing.  Trea tments include an adhesive bandage that is 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 67 / 75   considered the , a marketed adhesive bandage benchmark contr ol, a non-marketed adhesive bandage 
benchmark control, four non-marketed adhesive bandages, and no treatment (uncovered, negative 
control).   
 
 
Once a wound site has completely healed, bandage c hanges will be discontinued and the 
wound will be left uncovered.  
 
2.4. IPs (Section 6.5.2) 
 
Changed From: 
 
All IP application and removal  will be performed at the study s ite as described below by [CONTACT_874449] (see  section 6.6).  
 
 
 
 
 
 
 
Each IP unit is for single use; used bandages will not be re-applied and should be discarded by 
[CONTACT_874469] 6.3. 
 … 
 
 
  
 
 
 
Changed To: 
 
All IP application and removal  will be performed at the study s ite as described below by [CONTACT_874449] (see  section 6.6).  
 
 
 
 
 
 
 
 Each IP unit 
is for single use; used bandages will not be re-applied and sho uld be discarded by [CONTACT_874450] 6.3. 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 68 / 75   … 
 
 
  
 
 
 
Added: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
        
 
 
 
 
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 69 / 75    
 
 
  
 
   
 
  
2.5. Study Procedures and Evalua tion Schedule (Section 7.2) 
 
Note:  formatting change made in Table 2 to add footnotes to “Clinical grading of wound healing 
parameters” and “IP application” rows.   
 
 Changed From: 
 
DHealed test sites only.  
 Changed To: 
 
D At time of complete healing for a particular wound site. 
EClinical grading of wound healing parameters will be performed for a particular test site only until time 
of complete healing.  
FCompletely healed wound sites will be left uncovered for the re mainder of the study 
 
 
2.6.    Identification of Test Sites and Application of Temporary (Semi-Permanent) Dot-
Tattoos and Test Site Labels (Section [IP_ADDRESS])  
Changed From: 
 
Eight test sites (i.e. wound sites) will be identified on the v olar forearms, four on each forearm, as shown 
in Figure 5.  
 
Figure 5.  Wound Site Placement 
 
Changed To: 
 
Eight test sites (i.e. wound sites) will be identified on the v olar forearms, four on each forearm, as shown 
in Figure 6.  
 
Figure 6.  Wound Site Placement 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 70 / 75   2.7. Visits 3-16 (Day 1-14) (Section 7.2.6) 
 
Changed From: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
o Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
o Instrumental measurements, as described in section [IP_ADDRESS]. 
x The designated IP will be applied to each test site per the ran domization schedule. 
 Changed To: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
o Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS].
i 
o Instrumental measurements, as described in section [IP_ADDRESS]. 
o  
 
x The designated IP will be applied to each test site per the randomization schedule.ii 
 
i Clinical grading of wound healing parameters will be performed for a particular test site only until time of complete healing  
ii Completely healed wound sites wi ll be left uncovered for the re mainder of the study.  
 
2.8. Visit 17-18 (Day 15-16) (Section 7.2.7) 
 
Changed From: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
x Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
x   
   
x At Visit 17: The designated IP will be applied to each test sit e per the randomization schedule. 
 
Changed To:  
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
x Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS].
i 
x   
x  
   
x At Visit 17: The designated IP will be applied to each test sit e per the randomization schedule.ii 
 
i Clinical grading of wound healing parameters will be performed for a particular test site only until time of complete healing  
ii Completely healed wound sites wi ll be left uncovered for the re mainder of the study.  
 
 
 
 
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 71 / 75   2.9.  
 
 
 
 
 
e 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 72 / 75   Appendix X.   Summary of Changes – Amendment [ADDRESS_1221198] Name: N/A 
Protocol Number: CCSTOH001689 
IND/IDE/Eudra CT: N/A 
Phase: N/A 
Sponsor: [COMPANY_012] Consumer, Inc. 
Version and Date  Amendment 3: Final Version 4.0, 28 Aug 2019 
Amendment 2: Final Version 3.0, 20 Aug 2019  
Amendment 1: Final Version 2.0, 12 Aug 2019 
Original: Final Version 1.0, 10 Jul 2019  
 
 
 
 
CONFIDENTIAL:  This document contains privileged and confidenti al information belonging to the 
Sponsor.  Except as otherwise agreed to in writing, by [CONTACT_874468] g or reviewing this document, you agree 
to hold the information contained herein in confidence and not copy or disclose it to others (except where 
required by [CONTACT_1289]) or use it for unauthorized purposes . In the event information is disclosed to 
others, as required by [CONTACT_1289], they must be informed th at the information is privileged and 
confidential and may not be further disclosed by [CONTACT_476]. These re strictions on disclosures will apply equally 
to all future information supplied to you that is indicated as privileged and confidential. You agree that no 
unpublished information contained herein will be published or d isclosed without the prior written approval 
of Sponsor. In the event of any actual or suspected breach of t his obligation, Sponsor must be promptly 
notified. 
 
Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 73 / 75   1. REASONS FOR THE AMENDMENT TO THE FINAL PROTOCOL 
 
Sections of protocol CCSTOH001689 , “A 28-Day, Single Center, Randomized, Comparator-
Controlled, Proof-of-Principle Study to Assess Wound Healing Ef ficacies of Different Adhesive 
Bandages ”, dated August 20, 2019 (Final Version 3.0), have been revised to conti nue the clinical 
grading of wound healing paramet ers until Day 16 for all wound sites.  
 2. PROTOCOL SECTIONS REVISED 
 
The protocol sections that were revised are detailed below. The  format is as follows: 
 
x The “Changed From” section represents original text in Protocol  # CCSTOH001689, 
Final Version 3.0, dated August 20, 2019, that was changed to new text in Final 
Version 4.0, dated August 28 , 2019. The revised text is indicated in the “Changed 
To” section.  
 
2.1. Synopsis (Measurement a nd/or Evaluation Schedule) 
 
Changed From: 
 
x Clinical Grading of Wound Healing Parameters (erythema, edema, epi[INVESTIGATOR_874395], 
crusting/scabbing, smoothness, and general wound appearance) – Day 0 through Day 16* (or until 
completely healed, if earlier) 
 
Changed To: 
 
x Clinical Grading of Wound Healing Parameters (erythema, edema, epi[INVESTIGATOR_874395], 
crusting/scabbing, smoothness, and general wound appearance) – Day 0 through Day 16*  
 
2.2. Study Design (Section 3.0) 
 
Changed From: 
 
Each wound site will be photographed (at all time points) and a ssessed at pre-specified intervals by [CONTACT_874470] (until Day 16 or completely  healed, if earlier),  
 and TEWL (until Day 14).  In addition, subjects will a ssess the wound sites vi a questionnaire from 
Day 0 to Day 4, and  
 
 
 
Changed To: 
 
Each wound site will be photographed (at all time points) and a ssessed at pre-specified intervals by [CONTACT_874470] (until Day 16), and TEWL (until Day 
14).  In addition, subjects will assess the wound sites via que s t i o n n a i r e  f r o m  D a y  0  t o  D a y  4 ,   
 
 
 

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 74 / 75   2.3. Study Procedures and Evaluation Schedule (Section 7.2) 
 
Note:  formatting change were made in Ta ble 2 to remove the footnote from the “Clinical grading 
of wound healing parameters”  row and to change the footnote on the “IP application” row  from F 
to E. 
 Changed From: 
 
EClinical grading of wound healing parameters will be performed for a particular test site only until time 
of complete healing.  
FCompletely healed wound sites will be left uncovered for the re mainder of the study 
 
Changed To: 
 
ECompletely healed wound sites will be left uncovered for the remainder of the study. 
 
2.4. Visits 3-16 (Day 1-14) (Section 7.2.6) 
 
Changed From: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
o Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS].i 
o Instrumental measurements, as described in section [IP_ADDRESS]. 
o  
x The designated IP will be applied to each test site per the ran domization schedule.ii 
 
i Clinical grading of wound healing parameters will be performed  for a particular test site only until time of complete healing  
ii Completely healed wou nd sites will be left uncovered for the r emainder of the study. 
 
Changed To: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
o Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
o Instrumental measurements, as described in section [IP_ADDRESS]. 
o  
x The designated IP will be applied to each test site per the randomization schedule.i 
 
i Completely healed wound sites will be left uncovered for the r emainder of the study.  
 
2.5. Visit 17-18 (Day 15-16) (Section 7.2.7) 
 
Changed From: 
 
x After the acclimation period, th e following evaluations will be  conducted for each test site: 
x Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS].i 
x   

Protocol Title: A 28-Day, Single-Center, Randomized, Comparator -Controlled, Proof-of-Principle Study to Assess Wound Healing E fficacies of 
Different Adhesive Bandages 
Protocol Number: CCSTOH001689 Version & Date:  Amendment 3: Fi nal Version 4.0, 28 Aug 2019 
 
Based on EFRM-0000805  Master Protocol Template – SOP-022190/SOP-0000574  Page 75 / 75   x  
  
x At Visit 17: The designated IP will be applied to each test sit e per the randomization schedule.ii 
 
i Clinical grading of wound healing parameters will be performed  for a particular test site only until time of complete healing  
ii Completely healed wou nd sites will be left uncovered for the r emainder of the study. 
 
Changed To: 
 
x After the acclimation period, the following evaluations will be  conducted for each test site: 
x Clinical Grading of Wound Healing Parameters, as described in s ection [IP_ADDRESS]. 
x   
  
   
x At Visit 17: The designated IP will be applied to each test sit e per the randomization schedule.ii 
 
ii Completely healed wou nd sites will be left uncovered for the r emainder of the study.  
